Drug Administration Compositions and Methods of Use thereof

Abstract

This document describes compositions for vaginal administration of an active agent or salt to a subject, comprising the active agent or salt thereof, a bioadhesive, and an emulsion. It also describes methods for treating a disease or condition by vaginally administering a pharmaceutical composition to a subject, and kits comprising the pharmaceutical composition.

Description

Drug Administration Compositions and Methods of Use thereof BRIEF DESCRIPTION OF THE INVENTION Methods are described herein comprising vaginally administering to a subject a pharmaceutical composition in the form of an emulsion that may comprise an active agent or a salt thereof and a bioadhesive; wherein a pharmaceutical composition may be administered in a dose of approximately 10 mg to approximately 400 mg of an active agent or a salt thereof; and wherein vaginal administration of a pharmaceutical composition produces a substantially zero-order release rate profile of an active agent in a subject's peritoneal cavity at least approximately 8 hours after administration of the pharmaceutical composition. In some embodiments, a dose may comprise approximately 50 mg to approximately 100 mg of an active agent or a salt thereof.In some embodiments, an active agent or a salt thereof may be present in the peritoneal cavity approximately 12 hours after administration of a pharmaceutical composition. In some embodiments, vaginal administration of a pharmaceutical composition produces a peritoneal concentration of an active agent, a metabolite thereof, or a salt thereof that may be at least approximately four times greater than a peritoneal concentration of an active agent, a metabolite thereof, or a salt thereof achieved through oral administration of an oral pharmaceutical composition that may comprise a substantially equivalent dosage of an active agent or a salt thereof. In some embodiments, the method may be a method for treating a disease or condition.In some modalities, a disease or condition may be selected from the group consisting of an endometrial disorder, a cancer, an inflammatory disorder, an infection, and any combination thereof. In some modalities, a disease or condition may be an endometrial disorder. In some modalities, an endometrial disorder may be endometriosis, adenomyosis, or a combination thereof. In some modalities, the amount of an endometrial deposit may be lower after vaginal administration of a pharmaceutical composition than the amount before vaginal administration of a pharmaceutical composition. In some modalities, a disease or condition may be a cancer. In some modalities, a cancer may be selected from the group consisting of cervical cancer; ovarian cancer; mesothelial cancer; peritoneal cancer; and any combination thereof.In some modalities, a treatment may involve reducing the size of a tumor or reducing tumor growth. In some modalities, a reduction in tumor size or growth may be determined by a reduction in tumor volume as measured by ultrasound. In some modalities, a disease or condition may be an inflammatory disorder. In some modalities, an inflammatory disorder may be selected from the group consisting of: pelvic inflammatory / infectious disease; chronic pelvic pain; and any combination thereof. In some modalities, a treatment may involve reducing the amount of at least one pro-inflammatory cytokine to a level that may be lower than prior to vaginal administration of a pharmaceutical composition. In some modalities, a disease or condition may be an infection.In some modalities, an infection may be a bacterial infection. In some modalities, an infection may be a viral infection. In some modalities, an infection may be a fungal infection. In some modalities, an active agent or salt thereof may be selected from the group consisting of a hormone; an antineoplastic agent; a GnRH agonist; a GnRH antagonist; a spheroid; an analgesic; an antibiotic; an antiviral compound; an antifungal compound; an anti-inflammatory agent; a salt of any of these; and any combination thereof. In some modalities, an active agent may be a hormone or a salt thereof. In some modalities, a hormone or salt thereof may be selected from the group consisting of: estradiol; ethinylestradiol; progesterone; levonorgestrel; desogestrel; a synthetic progesterone; a salt of any of these; and any combination thereof.In some formulations, an active agent may be an antineoplastic agent or a salt thereof. In some formulations, an antineoplastic agent or salt thereof may be selected from the group consisting of cyclophosphamide; methotrexate; 5-fluorouracil; doxorubicin; procarbazine; prednisolone; bleomycin; vinblastine; dacarbazine; cisplatin; epirubicin; dichloroacetate; a salt of any of these; and any combination thereof. In some formulations, an active agent may be a GnRH agonist or a GnRH antagonist or a salt thereof. In some formulations, a GnRH agonist or a GnRH antagonist or a salt thereof may be selected from the group consisting of leuprolide; buserelin; histrelin; goserelin; deslorelin; nafarelin; triptorelin; cetrorelix; abarelix; ganirelix, ozarelix, degarelix, or teverelix, or a salt of any of these; and any combination thereof. In some forms, an active agent may be a spheroid or a salt thereof.In some formulations, a spheroid or a salt thereof may be danazol or a salt thereof. In some formulations, an active agent may be an antibiotic or a salt thereof. In some formulations, an antibiotic or a salt thereof may be selected from the group consisting of ceftoliprole; ceftaroline; clindamycin; dalbavancin; daptomycin; linezolid; mupirocin; oritavancin; tedizolid; telavancin; tigecycline; vancomycin; an aminoglycoside; a carbapenem; ceftazidime; cefepime; ceftoliprole; a fluoroquinolone; piperacillin; ticarcillin; linezolid; streptogramin; tigecycline; daptomycin; a salt of any of these; and any combination thereof. In some formulations, an active agent may be an antiviral compound or a salt thereof.In some formulations, an antiviral compound or salt thereof may be selected from the group consisting of ceftobiprol; ceftaroline; clindamycin; dalbavancin; daptomycin; linezolid; mupirocin; oritavancin; tedizolid; telavancin; tigecycline; vancomycin; an aminoglycoside; a carbapenem; ceftazidime; cefepime; ceftobiprole; a fluoroquinolone; piperacillin; ticarcillin; linezolid; streptogramin; tigecycline; daptomycin; a salt of any of these; and any combination thereof. In some formulations, an active agent may be an antifungal compound or a salt thereof. In some formulations, an antifungal compound or salt thereof may be selected from the group consisting of ciclopirox olamine; haloprogin; tolnaftate; undecylenate; topical nysatin; amorolfine; butenafine; naftifine; terbinafine; a salt of any of these; and any combination thereof.In some formulations, an active agent may be an anti-inflammatory drug or a salt thereof. In some formulations, an anti-inflammatory drug or salt thereof may be selected from the group consisting of diclofenac, ketoprofen, ibuprofen, aspirin, a salt of any of these, and any combination thereof. In some formulations, a pharmaceutical composition may be administered in a dose of an active agent or salt thereof of at least approximately 50 mg, at least approximately 100 mg, at least approximately 150 mg, at least approximately 200 mg, at least approximately 250 mg, at least approximately 300 mg, at least approximately 350 mg, or at least approximately 400 mg. In some formulations, a pharmaceutical composition may be administered in a dose of an active agent or salt thereof per subject's body weight of at least approximately 0.1 mg / kg. approximately 0.5 mg / kg, at least approximately 1 mg / kg, at least approximately 1.5 mg / kg, at least approximately 2 mg / kg, at least approximately 2.5 mg / kg, at least approximately 3 mg / kg, at least approximately 3.5 mg / kg, at least approximately 4 mg / kg, at least approximately 4.5 mg / kg, at least approximately 5 mg / kg, at least approximately 5.5 mg / kg, at least approximately 6 mg / kg, at least approximately 6.5 mg / kg, at least approximately 7 mg / kg, at least approximately 7.5 mg / kg, at least approximately 8 mg / kg, at least approximately 8.5 mg / kg, at least approximately 9 mg / kg, at least approximately 9.5 mg / kg, at least approximately 10 mg / kg, at least approximately 11 mg / kg, at least approximately 12 mg / kg, at least approximately 13 mg / kg, at least approximately 14 mg / kg, at least approximately 15 mg / kg, at least approximately 16 mg / kg, at least approximately 17 mg / kg, at least approximately 18 mg / kg, at least approximately 19 mg / kg, or at least approximately 20 mg / kg. In some. In some embodiments, a pharmaceutical composition may comprise a substantially uniform mixture of an organic phase and an aqueous phase. In some embodiments, an organic phase may comprise at least one oleogel, which may comprise at least one oily agent and at least one water-insoluble cellulose polymer. In some embodiments, a water-insoluble cellulose polymer may be an alkyl cellulose. In some embodiments, an alkyl cellulose may be selected from the group consisting of methylcellulose, ethylcellulose, hydroxypropylcellulose, and any combination thereof. In some embodiments, a water-insoluble cellulose polymer may be a cellulose containing an alkyl carboxylic acid or a salt thereof. In some embodiments, a cellulose containing an alkyl carboxylic acid may be a carboxymethylcellulose that does not substantially contain sodium.In some embodiments, a carboxymethylcellulose not substantially containing sodium may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an alkyl cellulose may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an ethylcellulose may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, a cellulose containing an alkyl carboxylic acid or a salt thereof may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an aqueous phase may comprise at least one aqueous gel. In some embodiments, an aqueous gel may further comprise at least one gelling agent.In some embodiments, the at least one gelling agent may be selected from the group consisting of a carbomer, a poloxamer, sodium carboxymethylcellulose, and a combination thereof. In some embodiments, the at least one gelling agent may comprise from approximately 0.1% to approximately 10% by weight of a total weight of an aqueous gel. In some embodiments, the at least one gelling agent may comprise from approximately 0.01% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an oily agent may be selected from the group consisting of a monoglyceride, a diglyceride, a triglyceride, and any combination thereof. In some embodiments, an oily agent may be isolated and purified.In some embodiments, an oily agent may be selected from the group consisting of: a synthetic diglyceride; a synthetic triglyceride; propylene glycol isostearate; a mixture of polyoxyethylenelated oleic glycerides; an oil of plant origin; and any combination thereof. In some embodiments, propylene glycol isostearate may comprise from approximately 0.2% to approximately 2% by weight of a total weight of a pharmaceutical composition. In some embodiments, a mixture of polyoxyethylenelated oleic glycerides may comprise from approximately 0.2% to approximately 2% by weight of a total weight of a pharmaceutical composition. In some embodiments, an organic phase may be in a ratio of approximately 10:90 to approximately 90:10 by weight with respect to an aqueous phase.In some embodiments, a bioadhesive may be selected from the group consisting of: a carbomer; glyceryl monooleate; hypromellose; polycarbophil; poly(methyl vinyl ether co-maleic anhydride); a salt thereof; and a combination thereof. In some embodiments, a bioadhesive may be polycarbophil, a salt thereof, or a combination thereof. In some embodiments, a pharmaceutical composition may comprise an alcohol concentration of approximately 0% to approximately 4% by weight based on the total weight of the pharmaceutical composition, where the alcohol may be ethanol or isopropanol. In some embodiments, the alcohol concentration may be approximately 3.5% by weight based on the total weight of the pharmaceutical composition. In some embodiments, an active agent may comprise from approximately 0.00001% to approximately 10% by weight of the total weight of the pharmaceutical composition.In some embodiments, a pharmaceutical composition may comprise from approximately 0% to approximately 4% of a penetration enhancer by weight of the total weight of the pharmaceutical composition. In some embodiments, a pharmaceutical composition may comprise from approximately 0% to approximately 2% of a surfactant by weight of the total weight of the pharmaceutical composition, where a surfactant may be selected from the group consisting of nonionic, cationic, amphoteric, zwitterionic, and any combination thereof. In some embodiments, a pharmaceutical composition may be administered to a subject in a unit-dose form. In some embodiments, vaginal administration of a pharmaceutical composition may be carried out approximately every hour, approximately every 4 hours, approximately every 8 hours, approximately every 12 hours, or approximately every 24 hours.In some formulations, vaginal administration of a pharmaceutical composition may be performed approximately once, twice, three times, four times, five times, six times, seven times, or eight times within 24 hours. In some formulations, vaginal administration of a pharmaceutical composition may be performed approximately once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times, eleven times, twelve times, thirteen times, fourteen times, fifteen times, sixteen times, seventeen times, eighteen times, nineteen times, or twenty times per week.In some modalities, vaginal administration of a pharmaceutical composition can be carried out approximately once, cezQnn / eznz / e / Yi. approximately twice, approximately three times, approximately four times, approximately five times, approximately six times, approximately seven times, approximately eight times, approximately nine times, approximately ten times, approximately eleven times, approximately twelve times, approximately thirteen times, approximately fourteen times, approximately fifteen times, approximately sixteen times, approximately seventeen times, approximately seventeen times, approximately eighteen times, approximately nineteen times, approximately twenty-one times, approximately twenty-one times, approximately twenty-two times, approximately twenty-three times, approximately twenty-four times, approximately twenty-five times, approximately twenty-six times, approximately twenty-seven times, approximately twenty-eight times, approximately twenty-eight times cezQnn / eznz / e / Yi approximately 29 times, approximately 30 times, or approximately 31 times per month. In some embodiments, a pharmaceutical composition can be applied with a finger. In some embodiments, a pharmaceutical composition can be applied with a glove. In some embodiments, a pharmaceutical composition can be applied with an applicator. In some embodiments, vaginal administration may comprise intravaginal administration, topical administration, suppository administration, or any combination thereof. In some embodiments, a pharmaceutical composition maintains a substantially stable, uniform appearance for a period of approximately 1 year when stored in a sealed container at approximately 25°C, approximately 1 atm of pressure, and approximately 50% relative humidity.In some modalities, vaginal administration of a pharmaceutical composition produces a greater ability to achieve pregnancy after approximately 6 months of terminal vaginal administration of a pharmaceutical composition; with respect to oral administration of an oral pharmaceutical composition that may comprise a substantially equivalent amount of an active agent or salt thereof. Methods are also described herein that comprise vaginally administering to a subject a pharmaceutical composition in the form of an emulsion, which may comprise an active agent or a salt thereof and a bioadhesive; wherein vaginal administration of a pharmaceutical composition may comprise the administration of a dose of an active agent or a salt thereof; and wherein vaginal administration at least partially minimizes a side effect compared to oral administration of an oral pharmaceutical composition, which may comprise a substantially equivalent dose of an active agent or a salt thereof. In some embodiments, vaginal administration may be performed at least twice within 24 hours.In some modalities, a side effect may be selected from the group consisting of cardiotoxicity; renal toxicity; hepatotoxicity; and any combination thereof; as determined by a lower amount of a biomarker involved in a side effect following vaginal administration of a pharmaceutical composition with respect to an amount of a biomarker involved in a side effect following oral administration of an oral pharmaceutical composition.In some embodiments, vaginal administration of a pharmaceutical composition produces a peritoneal concentration of an active agent, a metabolite thereof, or a salt thereof that may be at least approximately four times greater than a peritoneal concentration of an active agent, a metabolite thereof, or a salt thereof achieved through oral administration of an oral pharmaceutical composition that may comprise a substantially equivalent dosage of an active agent or a salt thereof. In some embodiments, the method may be a method for treating a disease or condition. In some embodiments, a disease or condition may be selected from the group consisting of an endometrial disorder, a cancer, an inflammatory disorder, an infection, and any combination thereof. In some embodiments, a disease or condition may be an endometrial disorder.In some modalities, an endometrial disorder may be endometriosis, adenomyosis, or a combination of both. In some modalities, the amount of an endometrial deposit may be lower after vaginal administration of a pharmaceutical composition than before vaginal administration of a pharmaceutical composition. In some modalities, a disease or condition may be cancer. In some modalities, a cancer may be selected from the group consisting of cervical cancer; ovarian cancer; mesothelial cancer; peritoneal cancer; and any combination thereof. In some modalities, a treatment may comprise a reduction in tumor size or a reduction in tumor growth. In some modalities, a reduction in tumor size or a reduction in tumor growth may be determined by a reduction in tumor volume as measured by ultrasound.In some modalities, a disease or condition may be an inflammatory disorder. In some modalities, an inflammatory disorder may be selected from the group consisting of: pelvic inflammatory disease; chronic pelvic pain; and any combination thereof. In some modalities, a treatment may involve reducing the amount of at least one pro-inflammatory cytokine to a level that may be lower than prior to vaginal administration of a pharmaceutical composition. In some modalities, a disease or condition may be an infection. In some modalities, an infection may be a bacterial infection. In some modalities, an infection may be a viral infection. In some modalities, an infection may be a fungal infection.In some formulations, an active agent or salt thereof may be selected from the group consisting of a hormone; an antineoplastic agent; a GnRH agonist; a GnRH antagonist; a steroid; an analgesic; an antibiotic; an antiviral compound; an antifungal compound; an anti-inflammatory agent; a salt of any of these; and any combination thereof. In some formulations, an active agent may be a hormone or a salt thereof. In some formulations, a hormone or salt thereof may be selected from the group consisting of: estradiol; ethinylestradiol; progesterone; levonorgestrel; desogestrel; a synthetic progesterone; a salt of any of these; and any combination thereof. In some formulations, an active agent may be an antineoplastic agent or a salt thereof.In some formulations, an antineoplastic agent or salt thereof may be selected from the group consisting of cyclophosphamide; methotrexate; 5-fluorouracil; doxorubicin; procarbazine; prednisolone; bleomycin; vinblastine; dacarbazine; cisplatin; epirubicin; dichloroacetate; a salt of any of these; and any combination thereof. In some formulations, an active agent may be a GnRH agonist, a GnRH antagonist, or a salt thereof. In some formulations, a GnRH agonist or salt thereof may be selected from the group consisting of leuprolide; buserelin; histrelin; goserelin; deslorelin; nafarelin; triptorelin; a salt of any of these; and any combination thereof. In some formulations, an active agent may be a spheroid or a salt thereof. In some forms, a spheroid or salt thereof may be danazol or a salt thereof.In some modalities, a subject may be monitored for a period of at least 12 months after discontinuation of a course of treatment. In some modalities, an active agent may be an antibiotic or a salt thereof. In some modalities, an antibiotic or salt thereof may be selected from the group consisting of ceftoliprole; ceftaroline; clindamycin; dalbavancin; daptomycin; linezolid; mupirocin; oritavancin; tedizolid; telavancin; tigecycline; vancomycin; an aminoglycoside; a carbapenem; ceftazidime; cefepime; ceftoliprole; a fluoroquinolone; piperacillin; ticarcillin; linezolid; streptogramin; tigecycline; daptomycin; a salt of any of these; and any combination thereof. In some modalities, an active agent may be an antiviral compound or a salt thereof.In some formulations, an antiviral compound or salt thereof may be selected from the group consisting of ceftobiprol; ceftaroline; clindamycin; dalbavancin; daptomycin; linezolid; mupirocin; oritavancin; tedizolid; telavancin; tigecycline; vancomycin; an aminoglycoside; a carbapenem; ceftazidime; cefepime; ceftobiprole; a fluoroquinolone; piperacillin; ticarcillin; linezolid; streptogramin; tigecycline; daptomycin; a salt of any of these; and any combination thereof. In some formulations, an active agent may be an antifungal compound or a salt thereof. In some formulations, an antifungal compound or salt thereof may be selected from the group consisting of ciclopirox olamine; haloprogin; tolnaftate; undecylenate; topical nysatin; amorolfine; butenafine; naftifine; terbinafine; a salt of any of these; and any combination thereof.In some formulations, an active agent may be an anti-inflammatory drug or a salt thereof. In some formulations, an anti-inflammatory drug or salt thereof may be selected from the group consisting of diclofenac, ketoprofen, and ibuprofen. aspirin; a salt of any of these; and any combination thereof. In some embodiments, a pharmaceutical composition may be administered in a dose of an active agent or salt thereof of at least approximately 50 mg, at least approximately 100 mg, at least approximately 150 mg, at least approximately 200 mg, at least approximately 250 mg, at least approximately 300 mg, at least approximately 350 mg, or at least approximately 400 mg. In some embodiments, a pharmaceutical composition may be administered in a dose of an active agent or salt of aspirin; a salt of any of these; and any combination thereof. of the same per body weight of a subject of at least approximately 0.1 mg / kg, at least approximately 0.5 mg / kg, at least approximately 1 mg / kg, at least approximately 1.5 mg / kg, at least approximately 2 mg / kg, at least approximately 2.5 mg / kg, at least approximately 3 mg / kg, at least approximately 3.5 mg / kg, at least approximately 4 mg / kg, at least approximately 4.5 mg / kg, at least approximately 5 mg / kg, at least approximately 5.5 mg / kg, at least approximately 6 mg / kg, at least approximately 6.5 mg / kg, at least approximately 7 mg / kg, at least approximately 7.5 mg / kg, at least approximately 8 mg / kg, at least approximately 8.5 mg / kg, at least approximately 9 mg / kg, at least approximately 9.5 mg / kg, at least approximately 10 mg / kg, at least approximately 11 mg / kg, at least approximately 12 mg / kg, at least approximately 13 mg / kg, at least approximately 14 mg / kg, at least approximately 15 mg / kg, at least approximately 16 mg / kg, at least approximately 17 mg / kg, at least approximately 18 mg / kg, at least approximately 19 mg / kg, or at least approximately 20 mg / kg. In some. In some embodiments, a pharmaceutical composition may comprise a substantially uniform mixture of an organic phase and an aqueous phase. In some embodiments, an organic phase may comprise at least one oleogel, which may comprise at least one oily agent and at least one water-insoluble cellulose polymer. In some embodiments, a water-insoluble cellulose polymer may be an alkyl cellulose. In some embodiments, an alkyl cellulose may be selected from the group consisting of methylcellulose, ethylcellulose, hydroxypropylcellulose, and any combination thereof. In some embodiments, a water-insoluble cellulose polymer may be a cellulose containing an alkyl carboxylic acid or a salt thereof. In some embodiments, a cellulose containing an alkyl carboxylic acid may be a carboxymethylcellulose that does not substantially contain sodium.In some embodiments, a carboxymethylcellulose not substantially containing sodium may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an alkyl cellulose may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an ethylcellulose may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, a cellulose containing an alkyl carboxylic acid or a salt thereof may comprise from approximately 1% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an aqueous phase may comprise at least one aqueous gel. In some embodiments, an aqueous gel may further comprise at least one gelling agent.In some embodiments, the at least one gelling agent may be selected from the group consisting of a carbomer, a poloxamer, sodium carboxymethylcellulose, and a combination thereof. In some embodiments, the at least one gelling agent may comprise from approximately 0.1% to approximately 10% by weight of a total weight of an aqueous gel. In some embodiments, the at least one gelling agent may comprise from approximately 0.01% to approximately 10% by weight of a total weight of a pharmaceutical composition. In some embodiments, an oily agent may be selected from the group consisting of a monoglyceride, a diglyceride, a triglyceride, and any combination thereof. In some embodiments, an oily agent may be isolated and purified.In some embodiments, an oily agent may be selected from the group consisting of: a synthetic diglyceride; a synthetic triglyceride; propylene glycol isostearate; a mixture of polyoxyethylenelated oleic glycerides; an oil of plant origin; and any combination thereof. In some embodiments, propylene glycol isostearate may comprise from approximately 0.2% to approximately 2% by weight of a total weight of a pharmaceutical composition. In some embodiments, a mixture of polyoxyethylenelated oleic glycerides may comprise from approximately 0.2% to approximately 2% by weight of a total weight of a pharmaceutical composition. In some embodiments, an organic phase may be in a ratio of approximately 10:90 to approximately 90:10 by weight with respect to an aqueous phase.In some embodiments, a bioadhesive may be selected from the group consisting of: a carbomer; glyceryl monooleate; hypromellose; polycarbophil; poly(methyl vinyl ether co-maleic anhydride); a salt thereof; and a combination thereof. In some embodiments, a bioadhesive may be polycarbophil, a salt thereof, or a combination thereof. In some embodiments, a pharmaceutical composition may comprise an alcohol concentration of approximately 0% to approximately 4% by weight based on the total weight of the pharmaceutical composition, where the alcohol may be ethanol or isopropanol. In some embodiments, the alcohol concentration may be approximately 3.5% by weight based on the total weight of the pharmaceutical composition. In some embodiments, an active agent may comprise from approximately 0.00001% to approximately 10% by weight of the total weight of the pharmaceutical composition.In some forms, a pharmaceutical composition may comprise from approximately 0% to approximately. 4% of a penetration enhancer by weight of a total weight of a pharmaceutical composition. In some embodiments, a pharmaceutical composition may comprise from approximately 0% to approximately 2% of a surfactant by weight of a total weight of a pharmaceutical composition, where a surfactant may be selected from the group consisting of nonionic, cationic, amphoteric, zwitterionic, and any combination thereof. In some embodiments, a pharmaceutical composition may be administered to a subject in a unit-dose form. In some embodiments, vaginal administration of a pharmaceutical composition may be carried out approximately every hour. approximately every 4 hours, approximately every 8 hours, approximately every 12 hours, or approximately every 24 hours. In some formulations, vaginal administration of a pharmaceutical composition may be carried out approximately once, approximately twice, approximately 3 times, approximately 4 times, approximately 5 times, approximately 6 times, approximately 7 times, or approximately 8 times within 24 hours.In some modalities, vaginal administration of a pharmaceutical composition can be carried out approximately once, approximately twice, approximately 3 times, approximately 4 times, approximately 5 times, approximately 6 times, approximately 7 times, approximately 8 times, approximately 9 times, approximately 10 times, approximately 11 times, approximately 12 times, approximately 13 times, approximately 14 times, approximately 15 times, approximately 16 times, approximately 17 times, approximately 18 times, approximately 19 times, or approximately 20 times a week.In some modalities, vaginal administration of a pharmaceutical composition can be carried out approximately once, approximately twice, approximately 3 times, approximately 4 times, approximately 5 times, approximately 6 times, approximately 7 times, approximately 8 times, approximately 9 times, approximately 10 times, approximately 11 times, approximately 12 times, approximately 13 times, approximately 14 times, approximately 15 times, approximately 16 times, approximately 17 times, approximately 18 times, approximately 19 times, approximately 20 times, approximately 21 times, approximately 22 times, approximately 23 times, approximately 24 times, approximately 25 times, approximately 26 times, approximately 27 times, approximately 28 times. Approximately 29 times, approximately 30 times, or approximately 31 times per month. In some embodiments, a pharmaceutical composition can be applied with a finger. In some embodiments, a pharmaceutical composition can be applied with a glove. In some embodiments, a pharmaceutical composition can be applied with an applicator. In some embodiments, vaginal administration may comprise intravaginal administration, topical administration, suppository administration, or any combination thereof. In some embodiments, a pharmaceutical composition maintains a substantially stable, uniform appearance for a period of approximately 1 year when stored in a sealed container at approximately 25°C, approximately 1 atm of pressure, and approximately 50% relative humidity.In some modalities, vaginal administration of a pharmaceutical composition produces a greater ability to achieve pregnancy after approximately 6 months of terminal vaginal administration of a pharmaceutical composition; with respect to oral administration of an oral pharmaceutical composition that may comprise a substantially equivalent amount of an active agent or salt thereof. Pharmaceutical compositions comprising: (a) at least one oleogel, which may comprise at least one oily agent and at least one water-insoluble cellulose polymer; (b) at least one aqueous gel; (c) an active agent or a salt thereof; and (d) a bioadhesive; wherein an active agent or a salt thereof may be present in a pharmaceutical composition in an amount from approximately 50 mg to approximately 400 mg. In some embodiments, the at least one oleogel and the at least one aqueous gel may be in the form of an emulsion. In some embodiments, an active agent or a salt thereof may be selected from the group consisting of a hormone; an antineoplastic agent; a GnRH agonist; a GnRH antagonist; a spheroid; an analgesic; an antibiotic; an antiviral compound; an antifungal compound; an anti-inflammatory agent; a salt of any of these; and any combination thereof.In some formulations, an active agent may be a hormone or a salt thereof. In some formulations, a hormone or a salt thereof may be selected from the group consisting of: testosterone; estradiol; ethinylestradiol; progesterone; levonorgestrel; desogestrel; a synthetic progesterone; a salt of any of these; and any combination thereof. In some formulations, an active agent may be an antineoplastic agent or a salt thereof. In some formulations, an antineoplastic agent or a salt thereof may be selected from the group consisting of: cyclophosphamide; methotrexate; 5-fluorouracil; doxorubicin; procarbazine; prednisolone; bleomycin; vinblastine; dacarbazine; cisplatin; epirubicin; dichloroacetate; a salt of any of these; and any combination thereof. In some forms, an active agent may be a GnRH agonist, a GnRH antagonist, or a salt thereof.In some formulations, a GnRH agonist, GnRH antagonist, or salt thereof may be selected from the group consisting of leuprolide; buserelin; histrelin; goserelin; deslorelin; nafarelin; triptorelin; cetrorelix, abarelix; ganirelix, ozarelix, degarelix, or teverelix; a salt of any of these; and any combination thereof. In some formulations, an active agent may be a steroid or a salt thereof. In some formulations, a steroid or a salt thereof may be danazol or a salt thereof. In some formulations, an active agent may be an antibiotic or a salt thereof.In some formulations, an antibiotic or antibiotic salt may be selected from the group consisting of ceftobiprol; ceftaroline; clindamycin; dalbavancin; daptomycin; linezolid; mupirocin; oritavancin; tedizolid; telavancin; tigecycline; vancomycin; an aminoglycoside; a carbapenem; ceftazidime; cefepime; ceftobiprole; a fluoroquinolone; piperacillin; ticarcillin; linezolid; streptogramin; tigecycline; daptomycin; a salt of any of these; and any combination thereof. In some formulations, an active agent may be an antiviral compound or a salt thereof.In some formulations, an antiviral compound or salt thereof may be selected from the group consisting of ceftobiprol; ceftaroline; clindamycin; dalbavancin; daptomycin; linezolid; mupirocin; oritavancin; tedizolid; telavancin; tigecycline; vancomycin; an aminoglycoside; a carbapenem; ceftazidime; cefepime; ceftobiprole; a fluoroquinolone; piperacillin; ticarcillin; linezolid; streptogramin; tigecycline; daptomycin; a salt of any of these; and any combination thereof. In some formulations, an active agent may be an antifungal compound or a salt thereof. In some formulations, an antifungal compound or salt thereof may be selected from the group consisting of ciclopirox olamine; haloprogin; tolnaftate; undecylenate; topical nysatin; amorolfine; butenafine; naftifine; terbinafine; a salt of any of these; and any combination thereof.In some formulations, an active agent may be an anti-inflammatory drug or a salt thereof. In some formulations, an anti-inflammatory drug or salt thereof may be selected from the group consisting of diclofenac; ketoprofen; ibuprofen; aspirin; a salt of any of these; and any combination thereof. Also described herein are kits comprising a container that may contain a pharmaceutical agent described herein and instructions for use. Methods for manufacturing a kit comprising placing a pharmaceutical composition described herein into a container are also described herein. Methods for detecting danazol or a salt thereof in a sample are also described herein, comprising: (a) contacting a portion of a subject sample with an albumin; and (b) detecting danazol or a salt thereof by mass spectrometry. In some embodiments, a detection may comprise a determination of an amount of an [M+H]+ ion, which may comprise an m / z of 338. In some embodiments, a detection may comprise a comparison of an amount of an [M+H]+ ion, which may comprise an m / z of 338, to an amount of an [M+H]+ ion from an internal standard, where an internal standard may be 19-Norethindrone or a salt thereof. In some embodiments, an albumin may be human serum albumin. In some embodiments, a sample may be dried and reconstituted in a buffer solution between (a) and (b). cezQnn / eznz / e / Yi Also described herein are kits for determining the amount of danazol in a sample, comprising: (a) a sample collection container; (b) an albumin; and (c) instructions for use. In some embodiments, a kit may further comprise an internal standard, where an internal standard may be 19-Norethindrone or a salt thereof. In some embodiments, a kit may further comprise a buffer solution. In some embodiments, instructions for use instruct a user to: (a) collect a sample in a sample collection container; (b) contact a portion of a sample with a quantity of an albumin; and (c) detect danazol or a salt thereof by mass spectrometry. BRIEF DESCRIPTION OF THE DRAWINGS The novel features are set forth in detail in the appended claims. A better understanding of the features and advantages will be obtained by reference to the following detailed description, which sets forth illustrative embodiments in which exemplary principles are used, and the accompanying figures, of which FIGURE 1 represents an illustration of the peritoneal cavity and the organs contained within it. DETAILED DESCRIPTION OF THE INVENTION General Description Compositions and methods for vaginal drug administration are described herein to reach the pelvic area in such a way as to achieve high concentrations in peritoneal fluid and tissue with low levels detectable in the systemic circulation. In some cases, concentrations of at least 2 ng / mL, at least 5 ng / mL, at least >10 ng / mL, or even higher can be achieved. Compared with other methods of administration (e.g., oral administration), the drug delivery method described herein may improve therapeutic efficacy. In some cases, this administration may maintain a substantially zero-order release profile of a therapeutically effective amount of an active agent or salt thereof into peritoneal fluid over a given time interval when applied vaginally to a subject. This paper also describes methods for achieving a desired pharmacokinetic profile when administering a pharmaceutical composition vaginally to a subject. In some cases, the pharmaceutical composition may comprise an emulsion that can be mixed with an active agent or a bioadhesive. Vaginal administration of a pharmaceutical composition described herein may be used to deliver an active agent or a salt thereof locally into a peritoneal cavity. This administration may be used instead of systemic administration, thereby decreasing the amount of the active agent or salt thereof present in the circulation after vaginal administration of the pharmaceutical composition, compared to systemic administration (such as oral administration) of a pharmaceutical composition that may comprise a substantially equivalent dose of the active agent or a salt thereof. In some cases, the method described herein may reduce the potential for systemic adverse events and unwanted side effects that may occur with systemic administration of an active agent or salt thereof.The detection of an amount of an active agent or salt thereof in a sample from the subject is also contemplated using an assay that employs the detection of an albumin conjugate using mass spectrometry. The vaginal administration of a pharmaceutical composition may be used to treat a disease or condition in a subject. In some cases, a subject may be in need of such treatment, such as a subject who is suspected of having, or has been previously diagnosed with, a disease or condition treatable by vaginal administration of a pharmaceutical composition described herein. A pharmaceutical composition described herein may include at least one active agent, which may be selected based on the disease or condition being treated. Also described herein are kits that may comprise a pharmaceutical composition described herein. This kit may include instructions for applying a pharmaceutical composition, and means for applying the pharmaceutical composition. Definitions The terminology used herein is for the purpose of describing particular cases only and is not intended to be exhaustive. As used herein, the singular forms “a,” “one,” and “the” may be proposed to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including,” “containing,” “having,” “having,” or variants thereof may be used either in the detailed description and / or claims, these terms may be proposed to be inclusive in a manner similar to the term “comprising.” The term “around” or “approximately” can suggest within an acceptable range of error for a particular value as determined by ordinary experience in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measuring system. For example, “approximately” might mean approximately plus or minus 10%, in accordance with standard practice in the art. Alternatively, “approximately” might suggest a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with regard to biological systems or processes, the term might suggest within an order of magnitude, within 5 times, or within 2 times, of a value.Where particular values ​​can be described in the applications and claims, unless otherwise stated, the term “approximately” means within an acceptable error range for the particular value cezQnn / eznz / e / Yi to be assumed. Also, where ranges and / or sub-ranges of values ​​are provided, the ranges and / or sub-ranges may include the endpoints of the ranges and / or sub-ranges. The term “substantially,” as used herein, may refer to a value that is approximately 100% of a given value. For example, an active agent that is “substantially localized” in an organ may indicate that approximately 90% by weight of an active agent, salt, or metabolite may be present in that organ relative to the total amount of that active agent, salt, or metabolite. In some cases, the term may refer to an amount that is at least approximately 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 99.99% of a total amount. In some cases, the term may refer to an amount that is approximately 100% of a total amount. The term “subject,” “patient,” or “individual” as used herein may encompass a mammal and a non-mammal. A mammal may be any member of the class Mammalia, including but not limited to a human; non-human primates such as chimpanzees, apes, or other monkey species; a farm animal such as cattle, horses, sheep, goats, or pigs; a domestic animal such as a rabbit, dog (or canine), or cat (or feline); a laboratory animal, including a rodent such as a rat, mouse, or guinea pig, and the like. A non-mammal may include a bird, fish, and the like. In some modalities, a subject may be a mammal. In some modalities, a subject may be a human. In some cases, a human may be an adult. In some cases, a human may be a child. In some cases, a human may be 0–18 years of age. In some cases, a human may be 18–130 years of age. In some cases, a subject can be female.In some cases, a subject may be diagnosed with, or suspected of having, a condition or disease. A subject may be a patient. A subject may be an individual. In some cases, subject, patient, and individual may be used interchangeably. The term “prevent” may mean preventing additional symptoms, improving or preventing the underlying metabolic causes of symptoms, and may include prophylaxis. In some cases, “treat,” “treating,” “treatment,” “improvement,” or “that improves,” and other grammatical equivalents may include prophylaxis. “Treat,” “treating,” “treatment,” “improvement,” or “that improves,” and other grammatical equivalents may also include achieving a therapeutic and / or prophylactic benefit. Therapeutic benefit may mean the eradication of the underlying disease being treated. Alternatively, a therapeutic benefit may be achieved by eradicating one or more of the physiological symptoms associated with the underlying disease, such that an improvement may be observed in a subject even though, in some cases, the subject may still be affected by the underlying disease. cezQnn / eznz / e / Yi The terms “effective amount,” “therapeutically effective amount,” or “pharmaceutically effective amount,” as used herein, may refer to a sufficient quantity of a compound administered which will at least partially improve a symptom of a disease or condition being treated. The terms “compound,” “agent,” “active agent,” or “active ingredient” may be used to refer to a drug or therapeutic agent as described herein. In some cases, the terms “additional compound,” “additional agent,” or “additional therapeutic agent” may be used interchangeably to refer to other active compounds, agents, or therapeutic agents that may be used in a composition described herein. The terms “administer,” “administering,” “administration,” and similar terms, as used herein, may refer to methods that can be used to deliver compounds or compositions to the desired site of biological action. These methods may include oral administration, intraduodenal administration, parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular, or infusion), topical administration, and rectal administration. In some cases, a subject may administer the gel composition without supervision. In other cases, a subject may administer the gel composition under the supervision of a healthcare professional (e.g., a physician, nurse, physician assistant, hospice worker, care facility, etc.). In some exemplary embodiments, administration may be vaginal. Vaginal administration may include application to any surface of the vagina. In some cases, vaginal administration may be intravaginal. Vaginal administration may include applying a composition described herein to the vagina using a finger or an applicator. Vaginal administration may include intravaginal administration, topical administration to the vagina, and a combination of administrations. Vaginal administration may include administration via a carrier such as a patch, suppository, implantable depot, tablet, and the like. The term “pharmaceutically acceptable salt” or simply “salt” as used herein may refer to a salt that retains at least some of the biological effectiveness of the free acids and bases of the specified compound. In some cases, the salt may not be biologically or otherwise undesirable. In some embodiments, a compound described herein may possess acidic or basic groups and may therefore react with any of a variety of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, a salt may be prepared in situ during the final isolation and purification of a compound, or by separately reacting a purified compound in its free-base form with a suitable organic or inorganic acid and isolating the salt thus formed. Examples of pharmaceutically acceptable salts may include those prepared by the reaction of a compound described herein with a mineral, organic acid, or inorganic base. These salts may include acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bitartrate, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexene-1,6-dioate, hydroxybenzoate, γ-hydroxybutyrate, hydrochloride, and hydrobromide. iodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogen phosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate,nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulphylate, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate, undeconate, and xylenesulfonate. The term “pharmaceutical composition,” or simply “composition” as used herein, may refer to an active agent, optionally mixed with at least one pharmaceutically acceptable chemical component, such as a carrier, stabilizer, diluent, dispersing agent, suspending agent, thickening agent, excipient, bioadhesive, and the like. A delivery agent may be an emulsion comprising a substantially uniform mixture of an organic phase and an aqueous phase. An organic phase and an aqueous phase may comprise components dissolved or suspended therein. Although exemplary embodiments may describe the location of a component within a single phase, it is understood that any component may be present in any phase. The terms “co-administration,” “administered in combination with,” and their grammatical equivalents or similar terms, as used herein, may encompass the administration of selected therapeutic agents to an individual patient and may include treatment regimens in which the agents may be administered by the same or different routes of administration or at the same or different times. In some modalities, a compound described herein may be co-administered with other agents. These terms may encompass the administration of two or more agents to an animal such that both agents and / or their metabolites may be present in the animal at the same time. They may include simultaneous administration in separate compositions, administration at different times in separate compositions, and / or administration in a single composition in which both agents may be present.Thus, in some formulations, a compound and other agents can be administered in a single composition. In other formulations, a compound and other agents can be mixed within the composition. As used herein, the term “bioavailability” may indicate the degree to which a drug such as an active agent, salt, metabolite, or other substance becomes available to the target tissue after administration. Parameters frequently used in pharmacokinetic (PK) studies may include Tmax, Cmax, AUC(0-0°), AUC(0-t), T1 / 2, and CL / F. “Tmax” may refer to the time to reach maximum plasma concentration (“Cmax”) after administration of a therapeutic agent; “AUC(0-0°)” may refer to the area under the plasma concentration-time curve from time 0 to infinity; “AUC(0-t)” may refer to the area under the plasma concentration-time curve from time 0 to time t; “T1 / 2” may refer to the half-life of a therapeutic agent in blood plasma; “T1 / 2” may refer to the elimination half-life of the therapeutic agent from the circulation; and “CL / F” may refer to the apparent elimination rate of a therapeutic agent. The term “zero-order release rate profile” or “zero-order release profile” can refer to a profile in which a concentration of an active agent is released into a subject's vasculature at a constant rate over a given time interval. In some cases, an active agent may have a substantially zero-order release profile in a subject's serum, lymph, or peritoneal vasculature upon administration of the pharmaceutical composition. The term “substantially free” can be used to indicate certain ingredients that do not need to be included in a composition or mixture. The amount of the ingredient may be so small that it does not cause irritation or generate an odor that could be objectionable to a subject. In some cases, the amount by weight of these ingredients may be less than approximately 5%, less than approximately 4.5%, less than approximately 4%, less than approximately 3.5%, less than approximately 3%, less than approximately 2.5%, less than approximately 2%, less than approximately 1.5%, less than approximately 1%, or less than approximately 0.5%. In some cases, the amount by weight of these ingredients may be less than approximately 0.9%, less than approximately 0.8%, less than approximately 0.7%, less than approximately 0.6%, less than approximately 0.5%, less than approximately 0.4%, less than approximately 0.3%, or less than approximately 0.2%, or less than approximately 0.1%. In some cases, the amount by weight of these ingredients may be less than approximately 0.09%, less than approximately 0.08%, less than approximately 0.07%, less than approximately 0.06%, less than approximately cezQnn / eznz / e / Yi. 0.05%, less than approximately 0.04%, less than approximately 0.03%, less than approximately 0.02%, or less than approximately 0.01%. In some cases, the amount by weight of these ingredients may be from approximately 0.1% to approximately 5%, from approximately 0.1% to approximately 4.5%, from approximately 0.1% to approximately 4%, from approximately 0.1% to approximately 3.5%, from approximately 0.1% to approximately 3%, from approximately 0.1% to approximately 2.5%, from approximately 0.1% to approximately 2%, from approximately 0.1% to approximately 1.5%, from approximately 0.1% to approximately 1%, or from approximately 0.1% to approximately 0.5%. In some cases, the amount by weight of these ingredients may be 0%. The term “bioadhesive” as used herein may refer to a polymeric material that can create intimate contact between an active ingredient and a biological substrate. The term “mucoadhesion” may be used interchangeably to describe bioadhesion to a mucous membrane. The term “w / w”, as used herein, may refer to the weight of a component of a composition relative to the total weight of a composition. The term “emulsion” as used herein may refer to the dispersion of two or more liquids. In some cases, an emulsion may include a dispersion of an organic phase in an aqueous phase. In some cases, an emulsion may include a dispersion of an aqueous phase in an organic phase. In some cases, an emulsion may include a dispersion of one organic phase in another organic phase. In some cases, an emulsion may include a dispersion of one aqueous phase in another aqueous phase. In some cases, an emulsion may be a uniform dispersion of the two or more liquids. In some cases, an emulsion may be a non-uniform dispersion of the two or more liquids. The term “penetration enhancer,” as used herein, may refer to a compound added to a composition to improve the rate of penetration of an active agent or a salt thereof through the skin of a subject. Examples of penetration enhancers may include a sulfoxide (such as dimethyl sulfoxide, DMSO), an azone (such as laurocapram), pyrrolidone (such as 2-pyrrolidone, 2P), a Ci-Cs alcohol (such as methanol, ethanol, n-propanol, isopropanol, tert-butanol, pentanol, hexanol, cyclohexanol, heptanol, octanol, and the like), a glycol (such as propylene glycol), a surfactant, or a terpene. The terms “dose” and “dosage” can be used interchangeably to refer to a quantity of an active agent or a pharmaceutical composition administered to a subject. Formulation This document describes pharmaceutical compositions for the localized administration of an active agent or a salt thereof. In some cases, a pharmaceutical composition may comprise an emulsion, which may be a substantially uniform mixture of an organic phase and an aqueous phase, an active agent or a salt thereof, and a bioadhesive. In some formulations, a pharmaceutical composition can be designed for vaginal administration. The formulation of a pharmaceutical composition may include mixing an organic phase and an aqueous phase with a bioadhesive and an active agent or a salt thereof. To improve the delivery of an active agent or a salt thereof, bioadhesives can be used to adhere the pharmaceutical composition to an epithelial surface during vaginal administration. The inventors discovered the surprising and unexpected result that a pharmaceutical composition as described herein, comprising an emulsion, can prevent or minimize vaginal clumping or discharge when formulated with a bioadhesive by emulsifying the insoluble material, thereby minimizing or eliminating the unpleasant clumping or discharge. This emulsion may comprise a substantially uniform mixture of an organic phase and an aqueous phase containing an active agent or a salt thereof and a bioadhesive. It is envisaged that an aqueous phase and an organic phase can be provided as a uniform mixture, or that each component can be provided separately for mixing prior to administration. A person of ordinary skill in the art would be able to formulate either the uniform mixture or separate phases depending on the application. An emulsion containing an organic phase and an aqueous phase may contain several components or ingredients. In some cases, an organic phase may contain at least one oleogel. An oleogel may comprise at least one oily agent and at least one polymer. An oily agent can be a monoglyceride, diglyceride, triglyceride, or any combination thereof. In some cases, an oily agent can be isolated and purified. In some cases, an oily agent can be a synthetic diglyceride, synthetic triglyceride, propylene glycol isostearate, a mixture of polyoxyethylenated oleic glycerides, an oil of natural plant origin, or any combination thereof. In some cases, an oily agent may be present in a proportion of approximately 0.1 to approximately 1%, 0.1 to approximately 2%, 0.1 to approximately 3%, 0.1 to approximately 4%, 0.1 to approximately 5%, 0.1 to approximately 6%, 0.1 to approximately 7%, 0.1 to approximately 8%, 0.1 to approximately 9%, 0.1 to approximately 10%, 0.1 to approximately 11%, 0.1 to approximately 12%, 0.1 to approximately 13%, 0.1 to approximately 14%, 0.1 to approximately 15%, 0.1 to approximately 16%, 0.1 to approximately 17%, 0.1 to approximately 18%, 0.1 to approximately 19%, 0.1 to approximately 20%, 0.1 to approximately 21%, 0.1 to approximately 22%, 0.1 to approximately 23%, 0.1a cezQnn / eznz / e / Yi approximately 24%, 0.1 to approximately 25%, 0.1 to approximately 26%, 0.1 to approximately 27%, 0.1 to approximately 28%, 0.1 to approximately 29%, or 0.1 to approximately 30% of the weight, with respect to the weight of the organic phase. In some cases, an oily agent may be present in a proportion of approximately 0.01 to approximately 0.1%, 0.01 to approximately 0.2%, 0.01 to approximately 0.3%, 0.01 to approximately 0.4%, 0.01 to approximately 0.5%, 0.01 to approximately 0.6%, 0.01 to approximately 0.7%, 0.01 to approximately 0.8%, 0.01 to approximately 0.9%, 0.01 to approximately 1%, 0.01 to approximately 2%, 0.01 to approximately 3%, 0.01 to approximately 4%, 0.01 to approximately 5%, 0.01 to approximately 6%, 0.01 to approximately 7%, 0.01 to approximately 8%, 0.01 to approximately 9%, 0.01 to approximately 10%. 0.01 to approximately 11%, 0.01 to approximately 12%, 0.01 to approximately 13%, 0.01 to approximately 14%, 0.01 to approximately 15%, 0.01 to approximately 16%, 0.01 to approximately 17%, 0.01 to approximately 18%, 0.01 to approximately 19%, 0.01 to approximately 20%, 0.01 to approximately 21%, 0.01 to approximately 22%, 0.01 to approximately 23%, 0.0.01 to approximately 24%, 0.01 to approximately 25%, 0.01 to approximately 26%, 0.01 to approximately 27%, 0.01 to approximately 28%, 0.01 to approximately 29%, or 0.01 to approximately 30% of the weight, with respect to the weight of the composition. In some exemplary embodiments, an oily agent may be propylene glycol isostearate. Exemplary pharmaceutical compositions may comprise propylene glycol isostearate in a proportion of between approximately 5 and 90% by weight, relative to the total weight of the oleogel. A mono-, di- or triglyceride can be a molecule of Formula I: cezQnn / eznz / e / Yi where Ri, R2 and R3 can be independently H; or C1-C20 alkyl comprising 0,1,2,3,4 or 5 degrees of unsaturation. In some respects, the synthetic mono- or di-triglycerides may be “LABRAFACMRlipophile WL1349”, sold by the Gatefosse company, propylene glycol isostearate, such as the product sold under the name “hydrophilol isostearique” by the Gatefosse company, and polyglycolized glyceride “LABRRAFILmrM 1944 CS” sold by Gatefosse. LABRAFILMRM 1944 CS is a mixture of polyoxyethylenated oleic glycerides obtained by the alcoholysis of natural plant oil. It can be an oily liquid whose properties are presented in Table 1 below. Table 1 cezQnn / eznz / e / Yi Chemical Name Polyglycolized oleic glyceride Trade Name LABRRAFILOM 1944 CS Dropping Point °C Liq. Saponification Number 1451175 Acid Number > 2 Iodine Number 60 / 90 Rat with acute oral toxicity OLD > 20mg / Kg LOP 0 HLB 314 In some cases, a mono-, di-, or triglyceride can be of natural or plant origin. A naturally occurring or plant-derived oil might include an oil such as sweet almond oil, argan oil, or palm oil. A polymer in an organic phase can be a cellulose polymer. In some cases, a cellulose polymer can be ethylcellulose, sodium-free carboxymethylcellulose, or a mixture thereof. In some cases, the polymer can be water-insoluble. In some exemplary embodiments, a water-insoluble polymer can be a water-insoluble cellulose polymer. A cellulose polymer can be a lipid-soluble cellulose polymer. In some cases, the cellulose polymer can be an alkylcellulose. In some cases, the alkylcellulose can be methylcellulose, ethylcellulose, hydroxypropylcellulose, or a combination thereof. In some cases, the cellulose polymer can be a cellulose containing an alkyl carboxylic acid or a salt thereof. In some cases, the cellulose containing an alkyl carboxylic acid can be sodium-free carboxymethylcellulose. In some cases, the water-insoluble polymer may be present in a proportion of approximately 0.1 to approximately 1%, 0.1 to approximately 2%, 0.1 to approximately 3%, 0.1 to approximately 4%, 0.1 to approximately 5%, 0.1 to approximately 6%, 0.1 to approximately 7%, 0.1 to approximately 8%, 0.1 to approximately 9%, 0.1 to approximately 10%, 0.1 to approximately 11%, 0.1 to approximately 12%, 0.1 to approximately 13%, 0.1 to approximately 14%, 0.1 to approximately 15%, 0.1 to approximately 16%, 0.1 to approximately 17%, 0.1 to approximately 18%, 0.1 to approximately 19%, 0.1 to approximately 20%, 0.1 to approximately 21%, 0.1 to approximately 22%, 0.1 to approximately 23%, 0.1 to approximately 24%, 0.1 to approximately 25%, 0.1 to approximately 26%, 0.1 to approximately 27%, 0.1 to approximately 28%, 0.1 to approximately 29%, or 0.1 to approximately 30% of the weight, with respect to the weight of the organic phase. In some cases, the water-insoluble polymer may be present in a proportion of approximately 0.01 to approximately 0.1%. 0.2%, 0.01 to approximately 0.3%, 0.01 to approximately 0.4%, 0.01 to approximately 0.5%, 0.01 to approximately 0.6%, 0.01 to approximately 0.7%, 0.01 to approximately 0.8%, 0.01 to approximately 0.9%, 0.01 to approximately 1%, 0.01 to approximately 2%, 0.01 to approximately 3%, 0.01 to approximately 4%, 0.01 to approximately 5%, 0.01 to approximately 6%, 0.01 to approximately 7%, 0.01 to approximately 8%, 0.01 to approximately 9%, 0.01 to approximately 10%, 0.01 to approximately 11%, 0.01 to approximately 12%, 0.01 to approximately 13%, 0.01 to approximately 14%, 0.01 to approximately 15%, 0.01 to approximately 16%, 0.01 to approximately 17%, 0.01 to approximately 18%, 0.01 to approximately 19%, 0.01 to approximately 20%, 0.01 to approximately 21%, 0.01 to approximately 22%, 0.01 to approximately 23%, 0.01 to approximately 24%, 0.01 to approximately 25%, 0.01 to approximately 26%, 0.01 to approximately 27%, 0.01 to approximately 28%, 0.01a approximately 29%, or 0.01 to approximately 30% of the weight, with respect to the weight of the composition. In some exemplary embodiments, a cellulose polymer may be present in a proportion of 1 to approximately 10% by weight. In some exemplary embodiments, a cellulose polymer may be ethylcellulose present in a proportion of 1 to approximately 10% by weight based on the total weight of a composition. In some cases, an oily agent may comprise LABRRAFILmrM 1944 CS. In some cases, the oily agent may be present in a proportion of between approximately 5 and 90% by weight, with respect to the total weight of the oleogel. In some cases, the ratio of the oleogel to the weight of the aqueous gel may be from approximately 10:90 to approximately 90:10. In some cases, the cellulose polymer may be EMULFREEMRP. In some cases, the cellulose polymer may be EMULFREEMRP and the oily agent may comprise LABRRAFILmrM 1944 CS. An aqueous phase as described herein may comprise one or more aqueous gels. The aqueous phase may comprise at least one aqueous gel. In some cases, an aqueous gel may comprise at least one gelling agent. A gelling agent may be a carbomer, poloxamer, sodium carboxymethylcellulose, or any mixture thereof. In some cases, the gelling agent may be present in a proportion of approximately 0.1 to approximately 1%, 0.1 to approximately 2%, 0.1 to approximately 3%, 0.1 to approximately 4%, 0.1 to approximately 5%, 0.1 to approximately 6%, 0.1 to approximately 7%, 0.1 to approximately 8%, 0.1 to approximately 9%, 0.1 to approximately 10%, 0.1 to approximately 11%, 0.1 to approximately 12%, approximately 15%, approximately 18%, approximately 21%, approximately 24%, 0.1 to approximately 13%, 0.1 to approximately 16%, 0.1 to approximately 19%, 0.1 to approximately 22%, 0.1 to approximately 25%, 0.1 to approximately 14%, 0.1 to 0.1 to approximately 17%, 0.1 to 0.1 to approximately 20%, 0.1 to 0.1 to approximately 23%, 0.1 to 0.1 to approximately 26%, 0.1 to approximately 27%, 0.1 to approximately 28%, 0.1 to approximately 29%, or 0.1 to approximately 30% of the weight, with respect to the weight of the aqueous phase. In some cases, a gelling agent may be present in a proportion of approximately 0.01 to approximately 0.1%, 0.01 to approximately 0.2%, 0.01 to approximately 0.3%, 0.01 to approximately 0.4%, 0.01 to approximately 0.5%, 0.01 to approximately 0.6%, 0.01 to approximately 0.7%, 0.01 to approximately 0.8%, 0.01 to about 0.9%, 0.01 to about 1%, 0.01 to about 2%, 0.01 to about 3%, 0.01 to about 4%, 0.01 to about 5%, 0.01 to about 6%, 0.01 to about 7%, 0.01 to about 8%, 0.01 to about 9%, 0.01 to about 10%, 0.01 to about 11%, 0.01 to about 12%, 0.01 to approximately 13%, 0.01 to approximately 14%, 0.01 to approximately 15%, 0.01 to approximately 16%, 0.01 to approximately 17%, 0.01 to approximately 18%, 0.01 to approximately 19%, 0.01 to approximately 20%, 0.01 to approximately 21%, 0.01 to approximately 22%, 0.01 to approximately 23%, 0.01 to approximately 24%, 0.01 to approximately 25%, 0.01 to approximately 26%, 0.01 to approximately 27%, 0.01 to approximately 28%, 0.01 to approximately 29%, or 0.01 to approximately 30% of the weight, with respect to the weight of the composition. In some respects, a gelling agent for the aqueous phase can be a carbomer, Carbopol 974 or Carbopol 980, present in a proportion of between approximately 0.1 and approximately 5% by weight, with respect to the total weight of the aqueous phase. In some cases, the weight ratio of the organic phase to the weight of the aqueous phase may be from approximately 1:9 to approximately 9:1, from approximately 1:8 to approximately 8:1, from approximately 1:7 to approximately 7:1, from approximately 1:6 to approximately 6:1, from approximately 1:5 to approximately 5:1, from approximately 1:4 to approximately 4:1, from approximately 1:3 to approximately 3:1, from approximately 1:2 to approximately 2:1, or from approximately 1:1.5 to approximately 1.5:1. In some cases, the weight ratio of the organic phase to the weight of the aqueous phase may be approximately 1:1. In some aspects, an emulsion in the composition of the present invention may comprise a substantially uniform mixture of an organic phase and an aqueous phase. In some cases, the weight ratio of the organic phase to the weight of the aqueous phase in this substantially uniform mixture may be approximately 1:1. In some cases, a uniform mixture of an organic phase and an aqueous phase can maintain a stable, uniform appearance for a period of time when stored in a sealed container. In some cases, the mixture can be stable for at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52 weeks. In some cases, the mixture may be stable for at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 months. In some cases, the mixture may be stable for at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years. In some cases, the sealed container may be stored at a temperature of approximately 25°C at a pressure of approximately 1 atm.In some cases, the sealed container can be stored at approximately 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% relative humidity. In some cases, the ratio of the volume of the organic phase to the volume of the aqueous phase can be from approximately 1:9 to approximately 9:1, from approximately 1:8 to approximately 8:1, from approximately 1:7 to approximately 7:1, from approximately 1:6 to approximately 6:1, from approximately 1:5 to approximately 5:1, from approximately 1:4 to approximately 4:1, from approximately 1:3 to approximately 3:1, from approximately 1:2 to approximately 2:1, or from approximately 1:1.5 to approximately 1.5:1. In some cases, the ratio of the volume of the organic phase to the volume of the aqueous phase can be approximately 1:1. An emulsion can include dispersions or droplets, as well as other lipid structures that can form as a result of hydrophobic forces that draw polar residues (e.g., long hydrocarbon chains) away from water and polar main groups toward water when an oily, water-immiscible phase is mixed with an aqueous phase. These other lipid structures can include unilamellar, paucilamellar, and multilamellar lipid vesicles, micelles, and lamellar phases. In some cases, a penetration enhancer may be present in a sufficient quantity to achieve an improved penetration rate. In some cases, a penetration enhancer does not improve the penetration rate of an active agent or its salt below a threshold concentration. A threshold concentration may be specific to a given penetration enhancer. In some cases, a penetration enhancer improves the absorption rate of an active agent or its salt when present at a weight concentration of at least approximately 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, cezQnn / eznz / B / Yi 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.51%, 0.52%, 0.53%, 0.54%, 0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.6%, 0.61%, 0.62%, 0.63%, 0.64%, 0.65%, 0.66%, 0.67%, 0.68%, 0.69%, 0.7%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, 0.77%, 0.78%, 0.79%, 0.8%, 0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%, 0.9%, 0.91%, 0.92%, 0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, cezQnn / eznz / e / Y 0.99%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69% or 70% by weight with respect to a total weight of a composition. In some cases, a composition described herein does not contain a penetration enhancer. In some cases, a composition described herein contains no more than approximately 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.51%, 0.52%, 0.53%, 0.54%, 0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.6%, 0.61%, 0.62%, 0.63%, 0.64%, 0.65%, 0.66%, 0.67%, 0.68%, 0.69%, 0.7%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, 0.77%, 0.78%, 0.79%, 0.8%, 0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%, 0.9%, 0.91%, 0.92%, 0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69% or 70% by weight of an improver of penetration with respect to a total weight of a composition. The oleogel and the aqueous phase may also comprise standard gel ingredients such as texturizing agents, antioxidants, preservatives, colorants or fragrances of various types and in conventional quantities that are known not to cause skin irritation. The composition may be in the form of a pharmaceutical formulation. In some cases, the pharmaceutical formulation may be administered similarly to a cosmetic product in the form of a cream or gel that can be applied to the skin. In some cases, the formulation may be in a unit-dose form when applied to at least one portion of skin in a specified quantity. Since the pharmaceutical formulation may comprise a stable mixture of an oleogel and an aqueous gel, it cannot be dirty or watery, and compared to conventional hydroalcoholic gels, it requires a smaller application area and may dry more quickly. In some cases, the gel composition may include a bioadhesive. Examples of bioadhesives may include carbomers, glyceryl monooleate, hypromellose, polycarbophil, poly(methyl vinyl ether co-maleic anhydride), and salts thereof. In some cases, a pharmaceutical composition may contain one or more bioadhesives. In some cases, a pharmaceutical composition may contain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bioadhesives. In some exemplary formulations, a bioadhesive can be polycarbophil or a salt thereof. Polycarbophil is designed to mimic negatively charged mucin, the glycoprotein component of mucus responsible for its adhesion to underlying epithelial surfaces. Polycarbophil is a loosely cross-linked polymer. It is also a weak polyacid containing multiple carboxyl (COO) radicals, the source of its negative charges. These acidic radicals can form hydrogen bonds with a cell surface. While hydrogen bonds can be weak, in the case of polycarbophil they can be numerous. Bioadhesives such as polycarbophil can remain attached to vaginal epithelial cells until they are turned over, which can take up to 7 days in postmenopausal women.However, clumping and vaginal discharge can occur because the water-insoluble polycarbophil remains bound to vaginal epithelial cells. Therefore, there is a need for a formulation that can ensure adherence of a pharmaceutical composition to a subject's epithelium while minimizing clumping or vaginal discharge. In some cases, a bioadhesive may be present at a weight concentration of at least approximately 0.01%, at least approximately 0.05%, at least approximately 0.1%, at least approximately 0.15%, at least approximately 0.2%, at least approximately 0.25%, at least approximately 0.3%, at least approximately 0.35%, at least approximately 0.4%, at least approximately 0.45%, at least approximately 0.5%, at least approximately 0.55%, at least approximately 0.6%, at least approximately 0.65%, at least approximately 0.7%, at least approximately 0.75%, at least approximately 0.8%, at least approximately 0.85%, at least approximately 0.9%, at least approximately 0.95%, at least approximately 1%, at least approximately 1.1%, at least approximately 1.2%, at least approximately 1.3%, at least approximately 1.4%, at least approximately 1.5%, at least approximately 1.6%, at least approximately 1.7%, at least approximately 1.8%, at least approximately 1.9%, at least approximately 2%, at least approximately 2.5%, at least approximately 3%, at least approximately 3.5%, at least approximately 4%, at least approximately 4.5%, at least approximately 5%, at least approximately cezQnn / eznz / e / Yi. 5.5%, at least approximately 6%, to at least approximately 6.5%, at least approximately 7%, at least approximately 7.5%, at least approximately 8%, at least approximately 8.5%, at least approximately 9%, at least approximately 9.5%, or at least approximately 10%. In some cases, a gel cezQnn / eznz / B / Yi 5 aqueous may comprise a polycarbophile in a weight concentration of 0.1% to 8%, 0.1% to 5%, from approximately 0.1% to 9%, 0.1% to 6%, from approximately 0.1% to 10%, 0.1% to 7%, 0.1% to approximately 10%, from approximately 0.1% to approximately 4%, from approximately 0.1% to approximately 3%, from approximately 0.1% to approximately 2%, from approximately 0.1% to approximately 1%, from approximately 0.1% to approximately 0.9%, from approximately 0.1% to approximately 0.8%, from approximately 0.1% to approximately 0.7%, from approximately 0.1% to approximately 0.6%, from approximately 0.1% to approximately 0.5%, from approximately 0.1% to approximately 0.4%, from approximately 0.1% to about 0.3%, or from about 0.1% to about 0.2%. The composition may include alcohol. For example, the alcohol may be a Ci-C8 alcohol. Examples of Ci-C8 alcohols may include methanol, ethanol, n-propanol, isopropanol, t-butanol, pentanol, hexanol, cyclohexanol, heptanol, octanol, and similar substances. Active Agents A pharmaceutical composition as described herein may comprise at least one active agent or salt thereof. While exemplary active agents are described herein, it is possible to substitute additional active agents in the composition in order to treat 25 other indications treatable by administering the pharmaceutical composition to a subject. In some respects, the active ingredients may be a hormone, anti-inflammatory, an analgesic, phenethylamine, antineoplastic, spheroid, 5-alpha reductase inhibitor, gonadotropin-releasing hormone (GnRH) agonist, GnRH 30 antagonist, a glycine receptor antagonist, tetrahydrocannabinol, an analgesic; antibiotic, an antiviral compound, an antifungal compound, a salt of any of these, or any combination thereof. In some cases, a hormone may be testosterone; dihydrotestosterone (DHT); estradiol; ethinylestradiol; progesterone; levonorgestrel; desogestrel; a peptide hormone such as oxytocin; a synthetic progesterone; a salt of any of these, or any combination thereof. In some cases, an active ingredient may be an analgesic. Analgesics may include acetaminophen, bromfenac, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, nepafenac, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, celecoxib, buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, tapentadol, tramadol, aspirin, a salt of any of these, or any combination thereof. In some cases, a phenethylamine may be dopamine, epinephrine, norepinephrine, phenylephrine, methylphenidate, amphetamine, a salt of any of these, or any combination thereof. In some cases, the antineoplastic agent may be cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, procarbazine, prednisolone, bleomycin, vinblastine, dacarbazine, cisplatin, epirubicin, dichloroacetate, a salt of any of these, or any combination thereof. In some cases, a spheroid may be danazol or a salt thereof. In some cases, a 5-alpha reductase inhibitor may be dutasteride, tamsulosin, finasteride, or a salt of any of these, or any combination thereof. In some cases, a GnRH agonist, a GnRH antagonist, may be leuprolide, buserelin, histrelin, goserelin, deslorelin, nafarelin, triptorelin, cetrorelix, abarelix; ganirelix, ozarelix, degarelix or teverelix, a salt of any of these, or any combination thereof. In some cases, a GnRH antagonist may be cetrorelix, abarelix; ganirelix, ozarelix, degarelix, teverelix, a salt of any of these, or any combination thereof. In some cases, a glycine receptor antagonist may be tranexamic acid or a salt thereof. In some cases, an antibiotic may be Ceftobiprole; Ceftaroline; Clindamycin; Dalbavancin; Daptomycin; Linezolid; Mupirocin; Oritavancin; Tedizolide; Telavancin; Tigecycline; Vancomycin; an Aminoglycoside; a Carbapenem; Ceftazidime; Cefepime; Ceftobiprole; a Fluoroquinolone; Piperacillin; Ticarcillin; Linezolid; Streptogramin; Tigecycline; Daptomycin; a salt of any of these; or any combination thereof. In some cases, an antiviral compound may be Ceftobiprole; Ceftaroline; Clindamycin; Dalbavancin; Daptomycin; Linezolid; Mupirocin; Oritavancin; Tedizolide; Telavancin; Tigecycline; Vancomycin; an Aminoglycoside; a Carbapenem; Ceftazidime; Cefepime; Ceftobiprole; a Fluoroquinolone; Piperacillin; Ticarcillin; Linezolid; Streptogramin; Tigecycline; Daptomycin; a salt of any of these; or any combination thereof. cezQnn / eznz / e / Yi In some cases, an antifungal compound may be ciclopirox olamine; haloprogine; tolnaftate; undecylenate; topical nysatin; amorolfine; butenafine; naftifine; terbinafine; or any combination thereof. In some respects, a composition may comprise no more than approximately 10 mg, no more than approximately 20 mg, no more than approximately mg, no more than approximately 60 mg, no more than approximately 80 mg, no more than approximately 100 mg, no more than approximately 140 mg, no more than approximately 180 mg, no more than approximately 120 mg, no more than approximately 160 mg, no more than approximately 200 mg, no more than approximately 300 mg, no more than approximately 400 mg, or no more than approximately 500 mg of an active agent or a salt thereof.In some cases, the composition may comprise at least approximately 10 mg, at least approximately 20 mg, at least approximately 40 mg, at least approximately 60 mg, at least approximately 80 mg, at least approximately 100 mg, at least approximately 120 mg, at least approximately 140 mg, at least approximately 160 mg, at least approximately 180 mg, at least approximately 200 mg, at least approximately 300 mg, at least approximately 400 mg, or at least approximately. 500 mg of an active agent or a salt thereof. An active agent may comprise a portion of the total weight of the composition. In some cases, an active agent may comprise from approximately 0.000001% to approximately 99%, from approximately 0.000001% to approximately 50%, from approximately 0.000001% to approximately 30%, from approximately 0.000001% to approximately 20%, from approximately 0.00005% to approximately 15%, from approximately 0.00005% to approximately 10%, from approximately 0.00001% to approximately 10%, from approximately 0.0001% to approximately 10%, or from approximately 0.0001% to approximately 5% by weight of the total weight of the composition. In some cases, the composition may include alcohol at a concentration that allows the active agent to dissolve. In some cases, the composition may have an alcohol concentration of at most approximately 10%, at most approximately 8%, at most approximately 6%, at most approximately 5%, at most approximately 4%, at most approximately 3%, at most approximately 2%, or at most approximately 1% by weight. In some cases, the alcohol concentration may be approximately 3.5% by weight. In some cases, the composition may be substantially free of a surfactant. In other cases, a composition may comprise small amounts of surfactants. Surfactants may be nonionic surfactants, cationic surfactants, amphoteric surfactants, or zwitterionic surfactants. In some cases, a composition may have a surfactant concentration of at most approximately 10%, at most approximately 8%, at most approximately 6%, at most approximately 5%, at most approximately 4%, at most approximately 3%, at most approximately 2%, at most approximately 1%, or at most approximately 0.1% of a surfactant by weight of the total weight of the composition. In cases where a composition comprises an active agent or a salt thereof, the active agent or a salt thereof can be emulsified in the emulsion. When emulsified in the emulsion, the active agent can be in a form with an average particle size minimized to approximately the micrometer scale. In some cases, the average particle size can be minimized to approximately the nanometer scale. In some cases, the average particle size can be from approximately 0.001 nm to approximately 500 pm, from approximately 0.001 nm to approximately 400 pm, from approximately 0.001 nm to approximately 300 pm, from approximately 0.001 nm to approximately 200 pm, from approximately 0.001 nm to approximately 100 pm, from approximately 0.001 nm to approximately 90 pm, from approximately 0.001 nm to approximately 80 pm, from approximately 0.001 nm to approximately 70 pm, from approximately 0.0.001 nm to approximately 60 pm, from approximately 0.001 nm to approximately 50 pm, from approximately 0.001 nm to approximately 40 pm, from approximately 0.001 nm to approximately 30 pm, from approximately 0.001 nm to approximately 20 pm, from approximately 0.001 nm to approximately 10 pm, from approximately 0.001 nm to approximately 5 pm, from approximately 0.001 nm to approximately 1 pm, from approximately 0.001 nm to approximately 900 nm, from approximately 0.001 nm to approximately 800 nm, from approximately 0.001 nm to approximately 700 nm, from approximately 0.001 nm to approximately 600 nm, from approximately 0.001 nm to approximately 500 nm, from approximately 0.001 nm to approximately 400 nm, from approximately 0.001 nm to approximately 300 nm, from approximately 0.001 nm to approximately 200 nm, from approximately 0.001 nm to approximately 100 nm, from approximately 0.001 nm to approximately 90 nm, from approximately 0.0.001 nm to approximately 80 nm, from approximately 0.001 nm to approximately 70 nm, from approximately 0.001 nm to approximately 60 nm, from approximately 0.001 nm to approximately 50 nm, from approximately 0.001 nm to approximately 40 nm, from approximately 0.001 nm to approximately 30 nm, from approximately 0.001 nm to approximately 20 nm, from approximately 0.001 nm to approximately 10 nm, from approximately 0.001 nm to approximately 5 nm, from approximately 0.001 nm to approximately 1 nm, from approximately 0.001 nm to approximately 0.9 nm, from approximately 0.001 nm to approximately 0.8 nm, from approximately 0.001 nm to approximately 0.7 nm, from approximately 0.001 nm to approximately 0.6 nm, from approximately 0.001 nm to approximately 0.5 nm, from approximately 0.001 nm to approximately 0.4 nm, from approximately 0.001 nm to approximately 0.3 nm, from approximately 0.001 nm to approximately 0.2 nm, from approximately 0.001 nm to approximately 0.1 nm, from approximately 0.001 nm to approximately 0.09 nm, from approximately 0.001 nm to approximately 0.08 nm, from approximately 0.001 nm to approximately 0.07 nm, from approximately 0.001 nm to approximately 0.06 nm, from approximately 0.001 nm to approximately 0.05 nm, from approximately 0.001 nm to approximately 0.04 nm, from approximately 0.001 nm to approximately 0.03 nm, from cezQnn / eznz / B / Yi. about 0.001 about 0.01 i nm to about 0.02 nm, or from nm. In some cases, the average particle size of approximately 0.001 nm can be approximately 0.01 nm, approximately 0.05 nm, approximately 0.1 nm, approximately 0.15 nm, approximately 0.2 nm, approximately 0.25 nm, approximately 0.3 nm, approximately 0.35 nm, approximately 0.4 nm, approximately 0.45 nm, approximately 0.5 nm, approximately 0.55 nm, approximately 0.6 nm, approximately 0.65 nm, approximately 0.7 nm, approximately 0.75 nm, approximately 0.8 nm, approximately 0.85 nm, approximately 0.9 nm, approximately 0.95 nm, approximately 1 nm, approximately 2 nm, approximately 3 nm, approximately 4 nm, approximately 5 nm, approximately 6 nm, approximately / nm, approximately 8 nm, approximately 9 nm, approximately 10 nm, approximately 15 nm, approximately 20 nm, approximately 25 nm, approximately 30 nm,25 approximately 35 nm, approximately 40 nm, approximately 45 nm, approximately 50 nm, approximately 55 nm, approximately 60 nm, approximately 65 nm, approximately 70 nm, approximately 75 nm, approximately 80 nm, approximately 85 nm, approximately 90 nm, approximately 95 nm, approximately 100 nm, approximately 150 nm, 30 approximately 200 nm, approximately 250 nm, approximately 300 nm, approximately 350 nm, approximately 400 nm, approximately 450 nm, approximately 500 nm, approximately 550 nm, approximately 600 nm, approximately 650 nm, approximately 700 nm, approximately 750 nm, approximately 800 nm, approximately 850 nm, approximately 900 nm, 35 approximately 950 nm, approximately 1 pm, approximately 2 pm, approximately 3 pm, approximately 4 pm, approximately 5 pm, approximately pm, approximately 7 pm, approximately 8 pm, approximately 9 pm, approximately 10 pm, 34 approximately 15 pm, approximately 20 pm, approximately 25 pm, approximately 30 pm, approximately 35 pm, approximately 40 pm, approximately 45 pm, approximately 50 pm, approximately 55 pm, approximately 60 pm, approximately 65 pm, approximately 70 pm, approximately 75 pm, approximately 80 pm, approximately 85 pm, approximately 90 pm, approximately 95 pm, approximately 100 pm, approximately 150 pm, approximately 200 pm, approximately 250 pm, approximately 300 pm, approximately approximately 400 pm, approximately 450 pm, or approximately 500 pm. Indicaciones 350 pm, cezQnn / eznz / e / Yi The methods and compositions can be used to treat a condition or disease. In some cases, treatment of a disease may include at least partially improving some of the symptoms of that disease or condition. Examples of a disease or condition that can be treated using a pharmaceutical composition as described herein may include an endometrial disorder, adenomyosis, cancer, an inflammatory disorder, an infection, and any combination thereof. Although exemplary diseases or conditions are cited herein, a person of ordinary skill in the art could use a pharmaceutical composition described herein to treat additional diseases or conditions by substituting additional active agents. In some cases, a disease or condition can be an endometrial disorder. For example, an endometrial disorder can be endometriosis. Endometriosis can be a common pain disorder in which the tissue that normally lines the inside of a uterus (e.g., the endometrium) grows outside the uterus (endometrial implant). Methods and compounds can be used to treat endometriosis involving the ovaries, bowel, or the tissue lining the pelvis, or endometriosis in which endometrial tissue spreads beyond a pelvic region. In endometriosis, the displaced deposits break down and bleed with each menstrual cycle. Because this displaced tissue has no way to leave the body, it can become trapped. The surrounding tissue can become irritated and eventually develop scarring and adhesions, the normal tissue that holds organs together.In some cases, treating the infection may involve reducing an endometrial deposit to an amount that may be lower than before treatment. In some cases, an endometrial disorder can be adenomyosis. Adenomyosis is a condition in which the inner lining of the endometrium ruptures through the muscular wall of the uterus (the myometrium). Adenomyosis can cause menstrual cramps, lower abdominal pressure, and bloating before periods, and may result in heavy periods. The condition can affect all parts of the uterus or be localized to one area. Although the cause of adenomyosis is unknown, studies have suggested that several hormones—including estrogen, progesterone, prolactin, and follicle-stimulating hormone—may trigger the condition. Current treatments may include administering an anti-inflammatory medication to reduce inflammation; administering an intervention such as an aromatase inhibitor, a GnRH agonist, or a GnRH antagonist to suppress the expression of hormones that may trigger the condition.In some cases, an incidence of adenomyosis and endometriosis may occur simultaneously. The treatment of an endometrial disorder using a vaginal composition as described herein can be determined using a variety of measurements known in the technique. A treatment endpoint for an endometrial disorder may include the ability to conceive. In some cases, the ability to conceive can be determined using an in vitro assay, such as a human chorionic gonadotropin (hCG) assay. An hCG assay can be performed on a sample from a subject, such as a blood sample. This assay could determine the level of hCG in the blood over time using an hCG-specific antibody, which can be used to determine the incidence of pregnancy. The ability to conceive can also be determined using an in vitro / vaginal imaging method such as ultrasound to determine the presence of mature oocytes within the subject, or to determine successful implantation of a zygote during fertilization. In some cases, a disease or condition may be cancer. For example, cancer may be cancer of the reproductive tract, cervical cancer, ovarian cancer, mesothelial cancer, peritoneal cancer, or any combination thereof. In exemplary modalities, vaginal administration of a pharmaceutical composition described herein can be used to treat peritoneal cavity cancer locally. Vaginal administration of a pharmaceutical composition described herein can be used to minimize adverse side effects that occur with systemic administration. For example, a pharmaceutical composition comprising an antineoplastic agent as described above can be used to deliver the antineoplastic agent directly into the peritoneal cavity with only minimal administration of the neoadjuvant into the circulatory system. As an exemplary illustration, this vaginal administration of a pharmaceutical composition can be used to mitigate known side effects of systemic antineoplastic administration, such as hair loss, reproductive side effects, skin or nail irritation, swelling, cardiotoxicity, hepatotoxicity, etc.The reduction of a side effect can be measured using specific methods, such as monitoring for a lower incidence of a side effect symptom. Examples include a reduction in local irritation or inflammation, a lower incidence of nausea, a lower incidence of pain, a reduction in irregular heart rate or arrhythmia, a decrease in excessively frequent or painful urination, etc. Biomarkers can also be used to measure a decrease in a side effect. In some cases, a reduction in a side effect may include a reduction in a biomarker associated with toxicity. In some cases, a reduction in a side effect may include an increase in a biomarker associated with toxicity.Examples of biomarkers may include cardiac troponin I, cardiac troponin T, serum alanine aminotransferase, glutathione-S-transferase alpha, aspartate aminotransferase, serum creatinine, blood urea nitrogen, kidney injury molecule-1, eutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), cystatin C, clusteinin, liver-type fatty acid-binding protein (L-FABP), osteopontin, etc. In some cases, cancer treatment may involve reducing tumor size or slowing or preventing tumor growth. A patient's tumor burden can be determined using imaging techniques such as ultrasound or magnetic resonance imaging (MRI), which can be compared over time to determine the therapeutic effect of administering the pharmaceutical composition. In some cases, the condition may be an inflammatory disorder. For example, the inflammatory disorder may be pelvic inflammatory disease, or chronic pelvic pain. Other examples of inflammatory disease include sepsis and chronic inflammation resulting from chronic viral or bacterial infection. In some cases, treatment of the condition may involve reducing the amount of at least one pro-inflammatory cytokine to a level lower than before treatment. In some cases, the condition may be an infection. For example, the infection may be a bacterial infection, a viral infection, a fungal infection, or any combination thereof. In some cases, an infection may include infection by a bacterial pathogen. A bacterial pathogen may be derived from a selected bacterial species from, but not exclusive to, the group consisting of: Staphylococcus spp., for example, Staphylococcus aureus (e.g., Staphylococcus aureus NCTC 10442 and Staphylococcus aureus ATCC25923), Staphylococcus epidermidis; Chlamydia spp., for example, Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci; Enterococcus spp., for example, Enterococcus faecalis; Streptococcus pyogenes; Listeria spp.; Pseudomonas spp.; Mycobacterium spp., for example, Mycobacterium tuberculosis complex; Enterobacter spp.; Campylobacter spp.; Salmonella spp.; Streptococcus spp., for example Streptococcus Group A or B, Streptococcus pneumoniae; Helicobacter spp., for example Helicobacter pylori, Helicobacter felis; Neisseria spp., for example Neisseria gonorrhoea, Neisseria meningitidis; Borrelia burgdorferi; Shigella spp., for example Shigella flexneri; Escherichia coli (E.coli 0157:H7 NCTC 12900); Haemophilus spp., for example Haemophilus influenzae; Francisella tularensis; Bacillus spp., for example Bacillus anthraces; Clostridia spp., for example cezQnn / eznz / e / Yi. Clostridium botulinum, Clostridium difficile; Yersinia spp., e.g. Yersinia pestis; Treponema spp.; Burkholderia spp., e.g. Burkholderia cepacia complex, B. mallei, B pseudomallei; Propionibacterium spp., e.g. P. acnes, Acinetobacter species, an Actinomyces species, a Campylobacter species, a Candida species, Corynebacterium minutissium, Corynebacterium pseudodiphthehae, Corynebacterium stratium, Corynebacterium group G1, Corynebacterium group G2, Enterobacteriaceae, an Enterococcus species, Klebsiella pneumoniae, a Moraxella species, a nontuberculous mycobacteria species, a Porphyromonas species, Prevotella melaninogenicus, Salmonella typhimurium, Serratia marcescens Streptococcus agalactiae, Staphylococcus salivarius, Streptococcus mitis, Streptococcus sanguis, Streptococcus pneumoniae, Vibrio cholerae, a Coccidioides species, or a Cryptococcus species. In some cases, an infection may include infection by a virus. A virus may be derived from, but not exclusively from, the group of herpesviruses, fowlpox, hepadnavirus, a flavivirus, togavirus, coronavirus, hepatitis O, hepatitis D, an orthomyxovirus, papillomavirus, polyomavirus, parvovirus, cytomegalovirus, Epstein-Barr virus, small fowlpox virus, avian cow virus, avian sheep virus, an orf virus, avian monkey virus, vaccinia virus, paramyxovirus, retrovirus, adenovirus, rhabdovirus, buniavirus, filovirus, alphavirus, arenavirus, lentivirus, and any combination thereof. In some cases, the virus may be an enveloped virus.Examples of enveloped viruses may include: poxvirus, hepadnavirus, flavivirus, togavirus, coronavirus, hepatitis C, hepatitis D, an orthomyxovirus, cytomegalovirus, an Epstein-Barr virus, smallpox virus, avian cow virus, avian sheep virus, an orf virus, a monkey pox virus, vaccinia virus, rhabdovirus, buniavirus, filovirus, alphavirus, arenavirus, lentivirus, and the like. In some cases, an infection may include infection by a selected parasite from, but not limited to, the group consisting of Trypanosoma spp. (Trypanosoma cruzi, Trypanosoma brucei), Leishmania spp., Giardia spp., Trichomonas spp., Entamoeba spp., Naegleria spp., Acanthanioeba spp., Schistosoma spp., Plasmodium spp., Cryptosporidium spp., Isospora spp., Balantidium spp., Loa Loa, Ascaris lumbricoides, Dirofilaria immitis, and Toxoplasma spp., for example Toxoplasma gondii. A fungal pathogen can be derived from a fungus (including yeast) selected from, but not limited to, the genera Candida spp., (e.g. C. albicans), Epidermophyton spp., Exophiala spp., Microsporum spp., Trichophyton spp., (e.g. T. rubrum and T. interdigitale), Tinea spp., Aspergillus spp., Blastomyces spp., Blastoschizomyces spp., Coccidioides spp., Cryptococcus spp. (e.g. Cryptococcus neoformans), Histoplasma spp., Paracoccidiomyces spp., Sporotrix spp., Absidia spp., Cladophialophora spp., Fonsecaea spp., Phialophora spp., Lacazia spp., Arthrographis spp., Acremoniwn spp., Actinomadura spp., Apophysomyces spp., Emmonsia spp., Basidiobolus spp., Beauveria spp., cezQnn / eznz / e / Yi Chrysosporium spp., Conidiobolus spp., Cunninghamella spp., Fusarium spp., Geotrichum spp., Graphiwn spp., Leptosphaeria spp., Malassezia spp. (e.g. Malassezia Furfur), Mucor spp., Neotestudina spp., Nocardia spp., Nocardiopsis spp., Paecilomyces spp., Phoma spp., Piedraia spp., Pneunwcystis spp., Pseudallescheria spp., Pyrenochaeta spp., Rhizoinucor spp., Rhizopus spp., Rhodotorula spp., Saccharomyces spp., Scedosporium spp., Scopulariopsis spp., Sporobolomyces spp., S:yncephalastrum spp., Trichoderma spp., Trichosporon spp., Ulocladium spp., Ustilago spp., Verticillium spp., and Wangiella spp. It is also envisaged that a pharmaceutical composition described herein could be administered prophylactically to prevent the occurrence of a disease or condition described herein. For example, a pharmaceutical composition comprising an antibiotic could be administered vaginally to a subject prior to surgery to prevent peritoneal infection. Dosage / Pharmacokinetics In some cases, a pharmaceutical formulation may be formulated to optimize the pharmacokinetics / pharmacodynamics of an active agent or salt of the same content in the vaginal administration of a pharmaceutical composition to a subject. In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered in a dose of approximately 1 mg to approximately 1000 mg, approximately 5 mg to approximately 1000 mg, approximately 10 mg to approximately 1000 mg, approximately 15 mg to approximately 1000 mg, approximately 20 mg to approximately 1000 mg, approximately 25 mg to approximately 1000 mg, approximately 30 mg to approximately 1000 mg, approximately 35 mg to approximately 1000 mg, approximately 40 mg to approximately 1000 mg, approximately 45 mg to approximately 1000 mg, approximately 50 mg to approximately 1000 mg, approximately 55 mg to approximately 1000 mg, approximately 60 mg to approximately 1000 mg, approximately 65 mg to approximately 1000 mg, approximately 70 mg to approximately 1000 mg, from about 75 mg to about 1000 mg,from approximately 80 mg to approximately 1000 mg, from approximately 85 mg to approximately 1000 mg, from approximately 90 mg to approximately 1000 mg, from approximately 95 mg to approximately 1000 mg, from approximately 100 mg to approximately 1000 mg, from approximately 150 mg to approximately 1000 mg, from approximately 200 mg to approximately 1000 mg, from approximately 250 mg to approximately 1000 mg, from approximately 300 mg to approximately 1000 mg, from approximately 350 mg to approximately 1000 mg, from approximately 400 mg to approximately 1000 mg, from approximately 450 mg to approximately 1000 mg, from approximately 500 mg to approximately 1000 mg, from approximately 550 mg to approximately 1000 mg, from approximately 600 mg to approximately 1000 mg, from approximately 650 mg to approximately 1000 mg, from approximately 700 mg to approximately 1000 mg, from approximately 750 mg to approximately 1000 mg,from about 800 mg to about 1000 mg, from about 850 mg to about 1000 mg, from about 900 mg to about 1000 mg, or from about 950 mg to about 1000 mg., In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered in a dose of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151,152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179 180, 181, 182, 183, 184, 184, 186, 187, 188, 189, 190, 191,192, 193, 194, 195, 196, 197, 198, 199, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, o 1000 mg. In some cases, a pharmaceutical composition comprising an active agent or a salt thereof described herein may be administered to provide a blood plasma concentration of an active agent, a metabolite thereof, or a salt thereof of approximately 0.5 ng / mL to approximately 10 pg / mL, approximately 1 ng / mL to approximately 10 pg / mL, approximately 5 ng / mL to approximately 10 pg / mL, approximately 10 ng / mL to approximately 10 pg / mL, approximately 15 ng / mL to approximately 10 pg / mL, approximately 20 ng / mL to approximately 10 pg / mL, approximately 25 ng / mL to approximately 10 pg / mL, approximately 30 ng / mL to approximately 10 pg / mL, approximately 35 ng / mL to approximately 10 pg / mL, approximately 40 ng / mL to approximately 10 pg / mL, from about 45 ng / mL to about 10 pg / mL, from about 50 ng / mL to about 10 pg / mL, from about 55 ng / mL to about 10 pg / mL,from approximately 60 ng / mL to approximately 10 pg / mL, from approximately 65 ng / mL to approximately 10 pg / mL, from approximately 70 ng / mL to approximately 10 pg / mL, from approximately 75 ng / mL to approximately 10 pg / mL, from approximately 80 ng / mL to approximately 10 pg / mL, from approximately 85 ng / mL to approximately 10 pg / mL, from approximately 90 ng / mL to approximately 10 pg / mL, from approximately 95 ng / mL to approximately 10 pg / mL, from approximately 100 ng / mL to approximately 10 pg / mL, from approximately 200 ng / mL to approximately 10 pg / mL, from approximately 300 ng / mL to approximately 10 pg / mL, from approximately 400 ng / mL to approximately 10 pg / mL, approximately 500 ng / mL to approximately 10 pg / mL, approximately 600 ng / mL to approximately 10 pg / mL, approximately 700 ng / mL to approximately 10 pg / mL, approximately 800 ng / mL to approximately 10 pg / mL, approximately 900 ng / mL to approximately 10 pg / mL,or from approximately 1 pg / mL to approximately 10 pg / mL after a period of time from approximately 1 minute to approximately 1, 2, 3, 4, 5, 6, 7, or 10 or more hours. In some cases, a pharmaceutical composition comprising an active agent or a salt thereof described herein may be administered to provide a blood plasma concentration of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of at least approximately 200 ng / mL, 195 ng / mL, 190 ng / mL, 185 ng / mL, 180 ng / mL, 175 ng / mL, 170 ng / mL, 165 ng / mL, 160 ng / mL, 155 ng / mL, 150 ng / mL, 145 ng / mL, 140 ng / mL, 135 ng / mL, 130 ng / mL, 125 ng / mL, 120 ng / mL, 115 ng / mL, 110 ng / mL, 105 ng / mL, 100 ng / mL, 95 ng / mL, 90 ng / mL, 85 ng / mL, 80 ng / mL, 75 ng / mL, 70 ng / mL, 65 ng / mL, 60 ng / mL, 55 ng / mL, 50 ng / mL, 45 ng / mL, 40 ng / mL, 35 ng / mL, 30 ng / mL, 25 ng / mL, 20 ng / mL, 15 ng / mL, 10 ng / mL, or 5 ng / mL after a period of time from approximately 1 minute to approximately 1,2, 3, 4, 5, 6, 7, 8, 9, or 10 hours. En algunos casos a pharmaceutical composition that comprises an active agent or a salt of the same described in the present can be administered to provide a concentration of an active agent, a metabolite of the same, or a salt of the same in a fluid peritoneal after administration to a subject of at least 200 ng / mL, 195 ng / mL, 190 ng / mL, 185 ng / mL, 180 ng / mL, 175 ng / mL, 170 ng / mL, 165 ng / mL, 160 ng / mL, 155 ng / mL, 150 ng / mL, 145 ng / mL, 140 ng / mL, 135 ng / mL, 130 ng / mL, 125 ng / mL, 120 ng / mL, 115 ng / mL, 110 ng / mL, 105 ng / mL, 100 ng / mL, 95 ng / mL, 90 ng / mL, 85 ng / mL, 80 ng / mL, 75 ng / mL, 70 ng / mL, 65 ng / mL, 60 ng / mL, 55 ng / mL, 50 ng / mL, 45 ng / mL, 40 ng / mL, 35 ng / mL, 30 ng / mL, 25 ng / mL, 20 ng / mL, 15 ng / mL, 10 ng / mL, 9 ng / mL, 8 ng / mL, 7 ng / mL, 6 ng / mL, 5 ng / mL, 4 ng / mL, 3 ng / mL, 2 ng / mL, 1 ng / mL, 0.9 ng / mL, 0.8 ng / mL, 0.7 ng / mL, 0.6 ng / mL, 0.5 ng / mL, 0.4 ng / mL, 0.3 ng / mL, 0.2 ng / mL, or 0.1 ng / mL after a time period of approximately 1 minute to approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours. In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a concentration of an active agent, a metabolite thereof, or a salt thereof in peritoneal fluid after administration to a subject of approximately 0.5 ng / mL to approximately 100 ng / mL, from approximately 0.5 ng / mL to approximately 90 ng / mL, from approximately 0.5 ng / mL to approximately 80 ng / mL, from approximately 0.5 ng / mL to approximately 70 ng / mL, from approximately 0.5 ng / mL to approximately 60 ng / mL, from approximately 0.5 ng / mL to approximately 50 ng / mL, from approximately 0.5 ng / mL to approximately 40 ng / mL, from approximately 0.5 ng / mL to approximately 30 ng / mL, from approximately 0.5 ng / mL to approximately 20 ng / mL, from approximately 0.5 ng / mL to approximately 10 ng / mL, from approximately 0.5 ng / mL to approximately 9 ng / mL, from approximately 0.5 ng / mL to approximately 8 ng / mL, from approximately 0.5 ng / mL to approximately 7 ng / mL, from approximately 0.5 ng / mL to approximately 6 ng / mL, from approximately 0.5 ng / mL to approximately 5 ng / mL, from approximately 0.5 ng / mL to approximately 4 ng / mL, from approximately 0.5 ng / mL to approximately 3 ng / mL, from approximately 0.5 ng / mL to approximately 2 ng / mL, or from approximately 0.5 ng / mL to approximately 1 ng / mL after a period of time of approximately 1 minute to approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours. En algunos casos a pharmaceutical composition that comprises an active agent or a salt of the same described in the present can be administered to provide a concentration of an active agent, a metabolite of the same, or a salt of the same in a peritoneal tissue after administration to a subject of at least 200 ng / mg, 195 ng / mg, 190 ng / mg, 185 ng / mg, 180 ng / mg, 175 ng / mg, 170 ng / mg, 165 ng / mg, 160 ng / mg, 155 ng / mg, 150 ng / mg, 145 ng / mg, 140 ng / mg, 135 ng / mg, 130 ng / mg, 125 ng / mg, 120 ng / mg, 115 ng / mg, 110 ng / mg, 105 ng / mg, 100 ng / mg, 95 ng / mg, 90 ng / mg, 85 ng / mg, 80 ng / mg, 75 ng / mg, 70 ng / mg, 65 ng / mg, 60 ng / mg, 55 ng / mg, 50 ng / mg, 45 ng / mg, 40 ng / mg, 35 ng / mg, 30 ng / mg, 25 ng / mg, 20 ng / mg, 15 ng / mg, 10 ng / mg, 9 ng / mg, 8 ng / mg, 7 ng / mg, 6 ng / mg, 5 ng / mg, 4 ng / mg, 3 ng / mg, 2 ng / mg, 1 ng / mg, 0.9 ng / mg, 0.8 ng / mg, 0.7 ng / mg, 0.6 ng / mg, 0.5 ng / mg, 0.4 ng / mg, 0.3 ng / mg, 0.2 ng / mg, or 0.1 ng / mg after a period of time from approximately 1 minute to approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours. In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a concentration of an active agent, a metabolite thereof, or a salt thereof in peritoneal tissue after administration to a subject of approximately 0.5 ng / mg to approximately 100 ng / mg, approximately 0.5 ng / mg to approximately 90 ng / mg, approximately 0.5 ng / mg to approximately 80 ng / mg, approximately 0.5 ng / mg to approximately 70 ng / mg, approximately 0.5 ng / mg to approximately 60 ng / mg, approximately 0.5 ng / mg to approximately 50 ng / mg, approximately 0.5 ng / mg to approximately 40 ng / mg, approximately 0.5 ng / mg to approximately 30 ng / mg, approximately 0.5 ng / mg to approximately 20 ng / mg, approximately 0.5 ng / mg to approximately 10 ng / mg, from approximately 0.5 ng / mg to cezQnn / eznz / e / Yi approximately 9 ng / mg, from approximately 0.5 ng / mg to approximately 8 ng / mg, from approximately 0.5 ng / mg to approximately 7 ng / mg, from approximately 0.5 ng / mg to approximately 6 ng / mg, from approximately 0.5 ng / mg to approximately 5 ng / mg, from approximately 0.5 ng / mg to approximately 4 ng / mg, from approximately 0.5 ng / mg to approximately 3 ng / mg, from approximately 0.5 ng / mg to approximately 2 ng / mg, or from approximately 0.5 ng / mg to approximately 1 ng / mg after a period of time of approximately 1 minute to approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours. In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a Tmax of an active agent or salt thereof after administration to a subject of approximately 1 minute to approximately 600 minutes, approximately 1 minute to approximately 590 minutes, approximately 1 minute to approximately 580 minutes, approximately 1 minute to approximately 570 minutes, approximately 1 minute to approximately 560 minutes, approximately 1 minute to approximately 550 minutes, approximately 1 minute to approximately 540 minutes, approximately 1 minute to approximately 530 minutes, approximately 1 minute to approximately 520 minutes, approximately 1 minute to approximately 510 minutes, approximately 1 minute to approximately 500 minutes, approximately 1 minute to approximately 490 minutes,from approximately 1 minute to approximately 480 minutes, from approximately 1 minute to approximately 470 minutes, from approximately 1 minute to approximately 460 minutes, from approximately 1 minute to approximately 450 minutes, from approximately 1 minute to approximately 440 minutes, from approximately 1 minute to approximately 430 minutes, from approximately 1 minute to approximately 420 minutes, from approximately 1 minute to approximately 410 minutes, from approximately 1 minute to approximately 400 minutes, from approximately 1 minute to approximately 390 minutes, from approximately 1 minute to approximately 380 minutes, from approximately 1 minute to approximately 370 minutes, from approximately 1 minute to approximately 360 minutes, from approximately 1 minute to approximately 350 minutes, from approximately 1 minute to approximately 340 minutes, from approximately 1 minute to approximately 330 minutes,from approximately 1 minute to approximately 320 minutes, from approximately 1 minute to approximately 310 minutes, from approximately 1 minute to approximately 300 minutes, from approximately 1 minute to approximately 290 minutes, from approximately 1 minute to approximately 280 minutes, from approximately 1 minute to approximately 270 minutes, from approximately 1 minute to approximately 260 minutes, from approximately 1 minute to approximately 250 minutes, from approximately 1 minute to approximately 240 minutes, from approximately 1 minute to approximately 230 minutes, from approximately 1 minute to approximately 220 minutes, from approximately 1 minute to approximately 210 minutes, from approximately 1 minute to approximately 200 minutes, from approximately 1 minute to approximately 190 minutes, from approximately 1 minute to approximately 180 minutes, from approximately 1 minute to approximately 170 minutes,from approximately 1 minute to approximately 160 minutes, from approximately 1 minute to approximately 150 minutes, from approximately 1 minute to approximately 140 minutes, from approximately 1 minute to approximately 130 minutes, from approximately 1 minute to approximately 120 minutes, from approximately 1 minute to approximately 110 minutes, from approximately 1 minute to approximately 100 minutes, from approximately 1 minute to approximately 90 minutes, from approximately 1 minute to approximately 80 minutes, from approximately 1 minute to approximately 70 minutes, from approximately 1 minute to approximately 60 minutes, from approximately 1 minute to approximately 50 minutes, from approximately 1 minute to approximately 40 minutes, from approximately 1 minute to approximately 30 minutes, from approximately 1 minute to approximately 20 minutes, from approximately 1 minute to approximately 10 minutes, from approximately 1 minute to approximately 9 minutes,from approximately 1 minute to approximately 8 minutes, from approximately 1 minute to approximately 7 minutes, from approximately 1 minute to approximately 6 minutes, from approximately 1 minute to approximately 5 minutes, from approximately 1 minute to approximately 4 minutes, from approximately 1 minute to approximately 3 minutes, or from approximately 1 minute to approximately 2 minutes. In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a Tmax of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131,132, 133, 134, 135, 136, 137, 138, 139, 140, 141,142, 143, 144, 145, 146, 147, 148, 149, 150,151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169,170, 171, 172, 173, 174, 175, 176, 177, 178, 179 180, 181, 182, 183, 184, 184, 186, 187, 188,189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200 minutes. In some cases, a pharmaceutical composition comprising an active agent or salt thereof described in the present CEZQnn / EZNZ / E / Yi may be administered to provide a Tmax of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of at least approximately 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8 6.9, or 7.0 hours. In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a Cmax of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of at least approximately 1,000 pg / mL, 950 pg / mL, 900 pg / mL, 850 pg / mL, 800 pg / mL, 750 pg / mL, 700 pg / mL, 650 pg / mL, 600 pg / mL, 550 pg / mL, 500 pg / mL, 450 pg / mL, 400 pg / mL, 350 pg / mL, 300 pg / mL, 250 pg / mL, 200 pg / mL, 150 pg / mL, 100 pg / mL, or 50 pg / mL.In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a Cmax of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of at least approximately 100 pg / mL, 95 pg / mL, 90 pg / mL, 85 pg / mL, 80 pg / mL, 75 pg / mL, 70 pg / mL, 65 pg / mL, 60 pg / mL, 55 pg / mL, 50 pg / mL, 45 pg / mL, 40 pg / mL, 35 pg / mL, 30 pg / mL, 25 pg / mL, 20 pg / mL, 15 pg / mL, 10 pg / mL, 5 pg / mL, 4 pg / mL, 3 pg / mL, 2 pg / mL, or 1 pg / mL.In some cases, an active agent, salt thereof, or pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a Cmax of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of at least approximately 1,000 ng / mL, 950 ng / mL, 900 ng / mL, 850 ng / mL, 800 ng / mL, 750 ng / mL, 700 ng / mL, 650 ng / mL, 600 ng / mL, 550 ng / mL, 500 ng / mL, 450 ng / mL, 400 ng / mL, 350 ng / mL, 300 ng / mL, 250 ng / mL, 200 ng / mL, 150 ng / mL, 100 ng / mL, or 50 ng / mL.In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein may be administered to provide a Cmax of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of at least approximately 100 ng / mL, 95 ng / mL, 90 ng / mL, 85 ng / mL, 80 ng / mL, 75 ng / mL, 70 ng / mL, 65 ng / mL, 60 ng / mL, 55 ng / mL, 50 ng / mL, 45 ng / mL, 40 ng / mL, 35 ng / mL, 30 ng / mL, 25 ng / mL, 20 ng / mL, 15 ng / mL, 10 ng / mL, or 5 ng / mL.In some cases, a pharmaceutical composition comprising an active agent or salt thereof described herein can be administered to provide a Cmax of an active agent, a metabolite thereof, or salt thereof of at least about 50 ng / mL, 49 ng / mL, 48 ng / mL, 47 ng / mL, 46 ng / mL, 45 ng / mL, 44 ng / mL, 43 ng / mL, 42 ng / mL, 41 ng / mL, 40 ng / mL, 39 ng / mL, 38 ng / mL, 37 ng / mL, 36 ng / mL, 35 ng / mL, 34 ng / mL, 33 ng / mL, 32 ng / mL, 31 ng / mL, 30 ng / mL, 29 ng / mL, 28 ng / mL, 27 ng / mL, 26 ng / mL, 25 ng / mL, 24 ng / mL, 23 ng / mL, 22 ng / mL, 21 ng / mL, 20 ng / mL, 19 ng / mL, cezQnn / eznz / e / Yi ng / mL, 17 ng / mL, 16 ng / mL, 15 ng / mL, 14 ng / mL, 13 ng / mL, 12 ng / mL, 11 ng / mL, 10 ng / mL, 9 ng / mL, 8 ng / mL, 7 ng / mL, 6 ng / mL, 5 ng / mL, 4 ng / mL, 3 ng / mL, 2 ng / mL, 1 ng / mL, or 0.5 ng / mL. In some cases, a pharmaceutical composition that includes an active agent or a salt of the same described in the present can be administered to provide an AUC(Of) of an active agent, a metabolite of the same, or a salt of the same after administration to a subject of at least 10,000 ng*h / mL, 9,900 ng*h / mL, 9,800 ng*h / mL, 9,700 ng*h / mL, 9,600 ng*h / mL, 9,500 ng*h / mL, 9,400 ng*h / mL, 9,300 ng*h / mL, 9,200 ng*h / mL, 9,100 ng*h / mL, 9,000 ng*h / mL, 8,900 ng*h / mL, 8,800 ng*h / mL, 8,700 ng*h / mL, 8,600 ng*h / mL, 8,500 ng*h / mL, 8,400 ng*h / mL, 8,300 ng*h / mL, 8,200 ng*h / mL, 8,100 ng*h / mL, 8,000 ng*h / mL, 7,900 ng*h / mL, 7,800 ng*h / mL, 7,700 ng*h / mL, 7,600 ng*h / mL, 7,500 ng*h / mL, 7,400 ng*h / mL, 7,300 ng*h / mL, 7,200 ng*h / mL, 7,100 ng*h / mL, 7,000 ng*h / mL, 6,900 ng*h / mL, 6,800 ng*h / mL, 6,700 ng*h / mL, 6,600 ng*h / mL, 6,500 ng*h / mL, 6,400 ng*h / mL, 6,300 ng*h / mL, 6,200 ng*h / mL, 6,100 ng*h / mL, 6,000 ng*h / mL, 5,900 ng*h / mL, 5,800 ng*h / mL, 5,700 ng*h / mL, 5,600 ng*h / mL, 5,500 ng*h / mL, 5,400 ng*h / mL, 5,300 ng*h / mL, 5,200 ng*h / mL, 5,100 ng*h / mL, 5,000 ng*h / mL, 4,500 ng*h / mL, 4,000 ng*h / mL, 3,500 ng*h / mL, 3,000 ng*h / mL, 2,500 ng*h / mL, 2,000 ng*h / mL, 1,500 ng*h / mL, or 1,900 ng*h / mL, where t may be at least about 1.2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 hours after administration of a pharmaceutical composition comprising an active agent or a salt thereof. In some cases, a pharmaceutical composition that includes an active agent or salt of the same described in the present can be administered to provide an AUC(Ot) of an active agent, a metabolite of the same, or a salt of the same after administration to a subject of at least 10,000 ng*h / mL, 9,900 ng*h / mL, 9,800 ng*h / mL, 9,700 ng*h / mL, 9,600 ng*h / mL, 9,500 ng*h / mL, 9,400 ng*h / mL, 9,300 ng*h / mL, 9,200 ng*h / mL, 9,100 ng*h / mL, 9,000 ng*h / mL, 8,900 ng*h / mL, 8,800 ng*h / mL, 8,700 ng*h / mL, 8,600 ng*h / mL, 8,500 ng*h / mL, 8,400 ng*h / mL, 8,300 ng*h / mL, 8,200 ng*h / mL, 8,100 ng*h / mL, 8,000 ng*h / mL, 7,900 ng*h / mL, 7,800 ng*h / mL, 7,700 ng*h / mL, 7,600 ng*h / mL, 7,500 ng*h / mL, 7,400 ng*h / mL, 7,300 ng*h / mL, 7,200 ng*h / mL, 7,100 ng*h / mL, 7,000 ng*h / mL, 6,900 ng*h / mL, 6,800 ng*h / mL, 6,700 ng*h / mL, 6,600 ng*h / mL, 6,500 ng*h / mL, 6,400 ng*h / mL, 6,300 ng*h / mL, 6,200 ng*h / mL, 6,100 ng*h / mL, 6,000 ng*h / mL, 5,900 ng*h / mL, 5,800 ng*h / mL, 5,700 ng*h / mL, 5,600 ng*h / mL, 5,500 ng*h / mL, 5,400 ng*h / mL, 5,300 ng*h / mL, 5,200 ng*h / mL, 5,100 ng*h / mL, 5,000 ng*h / mL, 4,500 ng*h / mL, 4,000 ng*h / mL, 3,500 ng*h / mL, 3,000 ng*h / mL, 2,500 ng*h / mL, 2,000 ng*h / mL, 1,500 ng*h / mL, or cezQnn / eznz / e / Yi, 1,900 ng*h / ml_, where t can be at least approximately 1,2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 days after administration of a pharmaceutical composition comprising an active agent or a salt thereof. In some exemplary embodiments, a pharmaceutical composition comprising an active agent or salt thereof described herein can be administered to provide an AL)C(Of) of an active agent, a metabolite thereof, or a salt thereof after administration to a subject of approximately 1,000 ng*h / ml to approximately 10,000 ng*h / ml, approximately 1,000 ng*h / ml to approximately 9,000 ng*h / ml, approximately 1,000 ng*h / ml to approximately 8,000 ng*h / ml, approximately 1,000 ng*h / ml to approximately 7,000 ng*h / ml, approximately 1,000 ng*h / ml to approximately 6,000 ng*h / ml, approximately 1,000 ng*h / ml to approximately 5,000 ng*h / ml, from approximately 1,000 ng*h / ml to approximately 4,000 ng*h / ml, from approximately 1,000 ng*h / ml to approximately 3,000 ng*h / ml, or from approximately 1,000 ng*h / ml to approximately 2,000 ng*h / mL, where t can be at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 days after administration of a pharmaceutical composition comprising an active agent or a salt thereof. In some exemplary embodiments, a pharmaceutical formulation can be produced such that when a pharmaceutical formulation is administered to a primate, an active agent or salt thereof may have a Tmax of approximately 1 minute to approximately 1 hour, a Cmax of approximately 1 minute to approximately 8 hours, an AUCo>24hr of approximately 0.1 pg.hr / L to approximately 1,000 pg.hr / L, a half-life of approximately 2 hours to approximately 24 hours, or a combination thereof. In some cases, a pharmaceutical formulation may be formulated such that, when administered to a subject, an active agent or salt thereof may be substantially localized in a peritoneal organ or tissue of that subject. Examples of organs or tissues of the peritoneal cavity may include those represented in Figure 1. A peritoneal cavity may contain peritoneal fluid. A peritoneal organ or tissue may include, but is not limited to: bladder, gallbladder, intestine, uterus, endometrium, myometrium, perimetrium, stomach, ovary, ovarian cortex, ovarian epithelium, liver, spleen, or kidney. cezQnn / eznz / e / Yi In some cases, when a pharmaceutical formulation is administered to a subject, an active agent may have a half-life of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121,122, 123, 124, 125, 126,127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141,142, 143, 144, 145,146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164,165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179 180, 181, 182, 183,184, 184, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200 minutes. In some cases, when a pharmaceutical formulation is administered to a subject, an active agent or salt thereof may have a half-life of approximately 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, ​​5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7.0 hours. In some cases, when a pharmaceutical formulation is administered to a subject, an active agent or salt thereof may have a half-life of approximately 1 minute to approximately 600 minutes, approximately 1 minute to approximately 590 minutes, approximately 1 minute to approximately 580 minutes, approximately 1 minute to approximately 570 minutes, or approximately 1 minute to approximately 560 minutes.from approximately 1 minute to approximately 550 minutes, from approximately 1 minute to approximately 540 minutes, from approximately 1 minute to approximately 530 minutes, from approximately 1 minute to approximately 520 minutes, from approximately 1 minute to approximately 510 minutes, from approximately 1 minute to approximately 500 minutes, from approximately 1 minute to approximately 490 minutes, from approximately 1 minute to approximately 480 minutes, from approximately 1 minute to approximately 470 minutes, from approximately 1 minute to approximately 460 minutes, from approximately 1 minute to approximately 450 minutes, from approximately 1 minute to approximately 440 minutes, from approximately 1 minute to approximately 430 minutes, from approximately 1 minute to approximately 420 minutes, from approximately 1 minute to approximately 410 minutes, from approximately 1 minute to approximately 400 minutes,from approximately 1 minute to approximately 390 minutes, from approximately 1 minute to approximately 380 minutes, from approximately 1 minute to approximately 370 minutes, from approximately 1 minute to approximately 360 minutes, from approximately 1 minute to approximately 350 minutes, from approximately 1 minute to approximately 340 minutes, from approximately 1 minute to approximately 330 minutes, from approximately 1 minute to approximately 320 minutes, from approximately 1 minute to approximately 310 minutes, from approximately 1 minute to approximately 300 minutes, from approximately 1 minute to approximately 290 minutes, from approximately 1 minute to approximately 280 minutes, from approximately 1 minute to approximately 270 minutes, from approximately 1 minute to approximately 260 minutes, from approximately 1 minute to approximately 250 minutes, from approximately 1 minute to approximately 240 minutes,from approximately 1 minute to approximately 230 minutes, from approximately 1 minute to approximately 220 minutes, from approximately 1 minute to approximately 210 minutes, from approximately 1 minute to approximately 200 minutes, from approximately 1 minute to approximately 190 minutes, from approximately 1 minute to approximately 180 minutes, from approximately 1 minute to approximately 170 minutes, from approximately 1 minute to approximately 160 minutes, from approximately 1 minute to approximately 150 minutes, from approximately 1 minute to approximately 140 minutes, from approximately 1 minute to approximately 130 minutes, from approximately 1 minute to approximately 120 minutes, from approximately 1 minute to approximately 110 minutes, from approximately 1 minute to approximately 100 minutes, from approximately 1 minute to approximately 90 minutes, from approximately 1 minute to approximately 80 minutes, from approximately 1 minute to approximately 70 minutes,from approximately 1 minute to approximately 60 minutes, from approximately 1 minute to approximately 50 minutes, from approximately 1 minute to approximately 40 minutes, from approximately 1 minute to approximately 30 minutes, from approximately 1 minute to approximately 20 minutes, from approximately 1 minute to approximately 10 minutes, from approximately 1 minute to approximately 9 minutes, from approximately 1 minute to approximately 8 minutes, from approximately 1 minute to approximately 7 minutes, from approximately 1 minute to approximately 6 minutes, from approximately 1 minute to approximately 5 minutes, from approximately 1 minute to approximately 4 minutes, from approximately 1 minute to approximately 3 minutes, or from approximately 1 minute to approximately 2 minutes. Detection Methods Methods for detecting an active agent, a metabolite thereof, or a salt thereof in a subject sample following administration of a pharmaceutical composition to the subject are also described herein. A subject sample may be blood or any excretory fluid. Non-limiting examples may include saliva, blood, serum, cerebrospinal fluid, semen, feces, plasma, or urine. cezonn / eznz / B / Yi In some exemplary embodiments, the method may be a method for detecting danazol or a salt thereof in a subject sample. A method may comprise contacting a portion of a subject sample with albumin and detecting danazol or a salt thereof by mass spectrometry. An albumin may include human or bovine albumin. In some cases, the albumin may be serum albumin. The detection of an active agent such as danazol can be carried out by contacting the active agent with albumin to form an albumin adduct and determining the presence of the adduct using mass spectrometry. A method may further comprise comparison to an internal standard. An exemplary internal standard may include 19-Norethindrone. A mass spectrometer may include a single or tandem mass spectrometer. A mass spectrometer may comprise an electrospray ionizer, an array-assisted laser desorption / ionization ionizer, an electron ionizer, a fast atom bombardment ionizer, or a chemical ionizer. An exemplary method may involve detecting danazol by determining the amount of an [M+H]+ ion. In some cases, an [M+H]+ ion may have an m / z of approximately 338. In some cases, a sample may dry out after contact with albumin. In some cases, a sample may be reconstituted, resuspended, or diluted in a resuspension buffer solution after contact with albumin.A re-suspension buffer solution can be a buffering agent such as saline, citrate, phosphate, phosphate-buffered saline, acetate, glycine, tris(hydroxymethyl)aminomethane(TRIS) hydrochloride, tris-buffered saline (TBS), 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-sulfonic acid (TAPS), bicine, tricine, 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]-2-hydroxypropane-1-sulfonic acid (TAPSO), 4-(2-hydroxyethyl)-1-piperazine-methanesulfonic acid (HEPES), piperazine-N,N'-bis(2-ethanesulfonic) acid (PIPES), acid 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2]amino]ethanesulfonic acid (TES), cacodylate, glycine, carbonate, or any combination thereof. Kits These kits are described herein. In some respects, a composition may be packaged in a container. In some respects, a kit may also include instructions for administering a single dose of a composition to a subject. Methods for manufacturing a kit may include placing a pharmaceutical composition in a container. A method may further include instructions for use. In some cases, the instructions for use may specify administering a single dose of a composition to a subject. Kits for determining the amount of danazol in a sample are also described herein. A kit may comprise: a sample collection container; an albumin; and instructions for use. In some cases, an internal standard may be 19-Norethindrone or a salt thereof. The instructions for use may instruct a user to: collect a sample in the sample collection container; contact a portion of the sample with a quantity of the albumin; and detect danazol or a salt thereof by mass spectrometry. In some cases, a kit may also comprise an internal standard. An internal standard may be 19-Norethindrone or a salt thereof. EXAMPLES Example 1: Formulation of a composition comprising a hormone for vaginal administration: An exemplary pharmaceutical composition containing a bioadhesive for delivering a hormone can be prepared for vaginal administration to a subject using the following formulation: Proquesterone Formulation (% w / w): Micronized Progesterone (USP / EP) 8.0% Carbomer (Carbopol 974P NF) 1.0% Policarbof i lo Noveon AA1 (USP) 1.5% Sorbic Acid (USP / EP) 0.1% Lipophilic Labrafac WL 1349 (USP / EP) 17.07% EmulFree P Pharma Grade 2.0% Purified Water (USP / EP) 68.4% Sodium Hydroxide (USP / EP) QS AD pH 2.8 -3.2 Purified Water (USP / EP) QS 100% The progesterone formulation can be prepared by dissolving micronized progesterone in an oil phase consisting of LABRAFACMRlipophille WL 1349 and EMULFREEMRP. Alcohol can be added to this suspension at a concentration where it does not act as a penetration enhancer. The carbomers will hydrate in the aqueous phase. After hydration, sorbic acid, polycarbophil, and sodium hydroxide will be added to the aqueous phase. The two phases will be mixed in a suitable container. The resulting composition will be stored in a sealed container prior to vaginal administration. In addition to progesterone P(4), any synthetic progestin could be formulated using the described formulation. Estradiol formulation: (% w / w) Micronized Estradiol (USP / EP) 0.1% Carbomer (Carbopol 974P NF) 1.0% Policarbof i lo Noveon AA1 (USP) 1.5% Sorbic acid (USP / EP) 0.1% Labrafac Lipophile WL 1349 (USP / EP) 17.07% EmulFree P Pharma Grade 2.0% Purified Water (USP / EP) 76.4% Sodium hydroxide (USP / EP) OS AD pH 2.8 -3.2 Purified Water (USP / EP) OS 100% cezQnn / eznz / e / Yi Any estrogen can be substituted with estradiol, for example, dienestrol, estriol, estrone, etc. Compositions containing a bioadhesive and other active ingredients can be prepared in a manner similar to the formulations described above. Other active ingredients may include other hormones; antineoplastic agents; receptor agonists or antagonists; spheroids; antibiotics; antiviral compounds; antifungal compounds; and anti-inflammatory agents. Example 2: Formulation of a composition comprising danazol for vaginal administration: An exemplary pharmaceutical composition containing a bioadhesive for administering danazol can be prepared for vaginal administration to a subject using the following formulation: Danazol formulation: (% w / w) Danazol 6.67% Carbomer (Carbopol 974P NF) 1.0% Noveon AA1 Polycarbophil (USP) 1.5% Methylparaben 0.25% Labrafac Lipophile WL 1349 (USP / EP) 15% EmulFree P Pharma Grade 2.0% Purified water (USP / EP) 73.58% The danazol formulation can be prepared by dissolving danazol in an oil phase consisting of LABRAFACMRlipophille WL 1349 and EMULFREEMRP. The carbomers will be hydrated in the aqueous phase. After hydration, methylparaben and polycarbophil will be added to the aqueous phase. The two phases will be mixed in a suitable container. The resulting composition will be stored in a sealed container prior to vaginal administration. Example 3: Pharmacokinetic studies in mice The following examples illustrate vaginal administration of a danazol formulation as described above in Example 2. Design by Studio cezQnn / eznz / e / Yi Group Number Number of Animals Active Ingredient Dose (mg) Formulation Route* 1 24 (3 per time point) 100 DANAZOL INTRAVAGINAL 2 24 (3 per time point) 100 DANAZOL ORAL 3 24 (3 per time point) 600 DANAZOL ORAL * Doses administered over ~ 30 seconds. Sample Collection Group Number Terminal Peritoneal Fluid Blood Collection Time 1-3 0.0333, 0.25, 0.5, 1,2, 4, 8, 24 hours post-dose (3 animals / time point) Anticoagulant K2EDTA Volume / Time Point Study Details Male CD-1 mice will be allowed to acclimate for a minimum of two days. A single dose of the danazol composition was administered intravaginally to mice in Group 1, while an oral formulation was administered to mice in Groups 2 and 3 via oral gavage. All animals were observed during dosing and at each scheduled collection. All abnormalities were recorded. Terminal blood samples were collected via cardiac puncture after inhalation anesthesia. Terminal peritoneal samples were collected by paracentesis. Sample Processing and Storage: Blood samples were collected in a tube containing dipotassium ethylenediaminetetraacetic acid (K2EDTA) and stored on moist ice. Whole blood was processed to plasma by centrifugation (3500 rpm at 5°C) within 30 minutes of collection. Plasma samples were divided into two equal aliquots, each transferred to a 96-well plate (matrix tube), and stored at -80°C until analysis. Administered doses were determined gravimetrically. Peritoneal fluid was collected using paracentesis at several time points. The samples were further subjected to high-performance liquid chromatography (HPLC) using a C18 column prior to MS / MS analysis. The HPLC-purified samples were contacted with human serum albumin to form albumin adducts, which can be detected using MS / MS by monitoring an m / z of approximately 338, corresponding to the [M+H]+ ion of the adduct. Results Pharmacokinetic parameters were calculated using non-compartmental methods with TK / PK analysis software. PK analysis was performed. All plasma and peritoneal fluid concentration data from all animals were included in the analysis. Example 4: Pharmacokinetic studies in humans The following example illustrates a vaginal administration of a danazol formulation as described above in Example 2 to a human subject. cezonn / eznz / B / Yi STUDY TYPE Comparative, Controlled Study. SUBJECT POPULATION Women with suspected or confirmed endometriosis scheduled for laparoscopy.STUDY TITLE Comparative, open-label, controlled, parallel-group study to determine intraperitoneal fluid, tissue, and serum concentrations of VML-0501 after five days of daily single-dose vaginal applications of VML-0501 (100 mg Danazol), compared to five days of treatment with Danazol administered as an oral tablet (Danatrol) at a daily dose of 600 mg, in two groups of twelve, each composed of women with suspected or confirmed endometriosis and scheduled for laparoscopy. TREATMENT DURATION PER SUBJECT 5-7 days OBJECTIVES To evaluate the bioavailability of VML-0501 compared to oral Danazol in terms of: Primary study outcome: - Measurement of serum concentrations (Study State) - Measurement of peritoneal fluid concentrations (Peritoneum, Study State). Secondary outcome of the study: - Concentration in endometrial tissue located outside the uterus (lesion tissue) METHODOLOGY Open-label parallel group study 5 INCLUSION CRITERIA Subjects may be admitted to the study if the subject: • Provides written informed consent (personally signed and dated) before completing any study-related procedure, which may mean any assessment or analysis that would not have been part of their personal medical care. • Is a woman who has or is suspected of having endometriosis scheduled to undergo laparoscopy. • Is 18 years of age or older and younger than 42 years of age. • Signs a specific clause to avoid pregnancy based on the use of two effective methods of birth control after 78 days following the last dose / application.• Not pregnant and undergoing laparoscopy for confirmed or suspected endometriosis within the first 10 days of her cycle. • Has a body mass index (BMI) <32 kg / m2. EXCLUSION CRITERIA Subjects cannot be admitted to the study if the subject: • Is pregnant (positive pregnancy test) or breastfeeding; • Has evidence of drug or alcohol abuse; • Has used hormone replacement therapy or Danazol therapy in the three months prior to study entry; • Has any of the following: epileptic seizures, migraine headache, angina, chronic heart failure, blood clot obstruction of a blood vessel, liver problems, kidney disease, pregnancy, elevated combined blood cholesterol and triglyceride levels, porphyria; • Has undiagnosed abnormal genital bleeding. • Has an androgen-dependent tumor. • Is allergic to anabolic androgen spheroids. • Is a smoker. STUDY MEDICINE, DOSAGE, AND ADMINISTRATION Subjects are assigned to one of two treatment options and matched according to proven infertility or endometriosis. The study medicine is applied to the upper part of the vagina using an applicator containing 100 mg of danazol for 5–7 consecutive days. Oral danazol (Danatrol): 200 mg capsules to be taken orally three times a day for 5–7 consecutive days. EVALUATION CRITERIA • Danazol concentration in peritoneal fluid. • Danazol concentration in endometrial lesion tissue. • Danazol concentration in serum. • Safety in terms of adverse events and inspection of the application site. STATISTICAL METHODS • Descriptive analyses to compare Danazol concentrations between groups in serum, peritoneal fluid, and injury tissue.• Analysis of adverse events. cezQnn / eznz / e / Yi An exemplary formulation of danazol, as described above with respect to Example 2, is administered for three months. Then, after a 30-day waiting period, pregnancy is allowed to occur. (Since danazol has a half-life of 9.7 hours, it can be expected that 3 days may be required to achieve zero drug concentration in the body.) Time-dependent blood samples are collected analogously to Example 3 to determine the PK parameters for circulating danazol. Peritoneal fluid samples are collected by paracentesis at various time points. The subject's samples are processed in a manner described above with respect to Example 3. The amount of danazol is determined in blood and peritoneal fluid samples using mass spectrometry as described above. Example 5: Treatment of Endometriosis Subjects previously diagnosed with endometriosis will be administered vaginally a pharmaceutical composition comprising danazol as described above with respect to Example 2. Clinical observation of safety parameters, including hemodynamic stability, acute immune response, cardiotoxicity, respiratory function, hepatotoxicity, kidney toxicity, and others, will be closely monitored. Blood samples will be collected for toxicity analysis. The treatment will be conducted for 30 days, with daily administration of the pharmaceutical composition to the subject. Endometrial deposits will be monitored to determine the treatment's effectiveness in improving the condition. Example 6: Ability to Get Pregnant After Treatment Subjects previously administered vaginally with a pharmaceutical composition comprising danazol in Example 5 may be further monitored after completion of the 30-day treatment. Improvement in the number of mature oocytes, implantation rates, and pregnancy rates following vaginally administered danazol treatment will be assessed to confirm fertility. Example 7: Ovarian Cancer Treatment A composition comprising doxorubicin is prepared analogously to the hormone or danazol formulations described in Examples 1 and 2. The composition is formulated such that applying a unit dose of the composition results in an application of approximately 100 mg of doxorubicin to the vagina. The subjects will receive a single dose of the doxorubicin composition administered intravaginally. Each subject will receive the respective treatment for 30 days. After each administration, each subject will be monitored for a reduction in ovarian tumor size using ultrasound to determine the efficacy of vaginal and oral administration. Example 8: Monitoring Cardiotoxicity Subjects administered doxorubicin vaginally or orally in Example 7 will be monitored for signs of cardiotoxicity during and after the course of treatment. Blood will be collected daily from each subject for the 30-day course of treatment. Cardiac troponin I and cardiac troponin T levels, which are biomarkers indicative of cardiac damage, will be assessed in each subject using a blood immunoassay specific to each biomarker. Samples from subjects who did not previously receive doxorubicin will be included as controls. The level of cardiotoxicity in subjects administered doxorubicin vaginally or orally will be assessed by monitoring for an increase in either cardiac troponin I or cardiac troponin T during the course of treatment, which will be compared to samples from subjects not administered doxorubicin. cezQnn / eznz / e / Yi Example 9: Treatment of Pelvic Inflammatory Disease A composition comprising the antibiotic appropriate to the disease-causing microbe can be formulated analogously to the hormone or danazol formulations described in Examples 1 and 2. A single dose of the levofloxacin-containing composition can be applied intravaginally to a subject previously diagnosed with an intraperitoneal infection using an applicator. The composition can be formulated such that applying a single dose results in the delivery of approximately 400 mg of the antibiotic to the vagina. Following application, the subject will be monitored for improvement of the infection. Example 10: Administration of Active Ingredients to the Peritoneal Cavity The following example illustrates the administration of either a vaginal or oral formulation of danazol to female human subjects. The vaginal formulation was prepared as described above in Example 2. The oral formulation contained a total dose of 200 mg of danazol present in a titanium dioxide and gelatin capsule body and was formulated with starch, lactose, talc, and magnesium stearate. The subjects were administered danazol daily for five days. Six subjects received a total dose of 600 mg of the oral danazol formulation (3 x 200 mg) once daily for five days. Seven subjects received the vaginal formulation containing a total of 100 mg of danazol. Samples were then taken from each subject to determine the concentration of danazol present systemically, in peritoneal fluid, and in peritoneal tissue. To quantify the amount of danazol present systemically, serum samples were collected from each subject and analyzed as described in Example 3 above. To determine the amount of danazol present in peritoneal fluid and tissue, endometrial lesions or suspected lesions were collected, and the amount of danazol present in the samples was quantified as described in Example 3. The results are shown in Table 2. cezgnn / eznz / B / Yi Table 2 Oral - 600mg Danazol Vaginal - 100mg Danazol Systemic (ng / mL) Peritoneal Fluid (ng / mL) Systemic (ng / mL) Peritoneal Fluid (ng / mL) Estimated Peritoneal Tissue (ng / mg) 198.3 130.7 7.3 1 29.2 113.4 67.7 4.4 1 17.6 209 134 2.1 1 8.4 141.3 16.2 3.3 1 13.2 167 132.8 3.4 1.2 13.6 109.7 19.2 4.3 1.6 17.2 - 4.1 1.8 16.4 Average 156.5 83.4 4.1 1.2 16.5 Standard Deviation 42.2 56.8 1.8 0.2 6.4 Variance 1778.5 3224.4 2.6 0.1 41.3 cezQnn / eznz / e / Yi Although the modalities have been shown and described herein, it will be obvious to those skilled in the art that these modalities are provided as examples only. Numerous variations, changes, and substitutions may be presented to those skilled in the art.

Claims

1. A method, characterized in that it comprises vaginally administering to a subject a pharmaceutical composition in the form of an emulsion comprising an active agent or salt thereof and a bioadhesive; wherein the pharmaceutical composition is administered in a dose of approximately 10 mg to approximately 400 mg of the active agent or salt thereof; and wherein the vaginal administration of the pharmaceutical composition produces a substantially zero-order release rate profile of the active agent in a peritoneal cavity of the subject at least approximately 8 hours after administration of the pharmaceutical composition.

2. The method according to claim 1, characterized in that the dose comprises from approximately 50 mg to approximately 100 mg of the active agent or a salt thereof.

3. The method according to claim 1 or 2, characterized in that the active agent or salt thereof is present in the peritoneal cavity approximately 12 hours after administration of the pharmaceutical composition.

4. A method, characterized in that it comprises vaginally administering to a subject a pharmaceutical composition in the form of an emulsion comprising: an active agent or salt thereof and a bioadhesive; wherein the vaginal administration of the pharmaceutical composition comprising an administration of a dose of the active agent or salt thereof; and wherein the vaginal administration at least partially minimizes a side effect compared to an oral administration of an oral pharmaceutical composition comprising a substantially equivalent dose of the active agent or salt thereof.

5. The method according to claim 4, characterized in that the vaginal administration is carried out at least 1, 2, 4, or 6 times within 24 hours.

6. The method according to claim 5, characterized in that the side effect is selected from the group consisting of cardiotoxicity; renal toxicity; hepatotoxicity; and any combination thereof; as determined by a lower amount of a biomarker involved in the side effect after vaginal administration of the pharmaceutical composition with respect to an amount of the biomarker involved in the side effect after oral administration of the oral pharmaceutical composition.

7. The method according to any of claims 1-6, characterized in that vaginal administration of the pharmaceutical composition produces a peritoneal concentration of the active agent, a metabolite thereof, or a salt thereof that is at least approximately 4 times greater than a peritoneal concentration of the active agent, metabolite thereof, or salt thereof achieved through oral administration of an oral pharmaceutical composition comprising a substantially equivalent dosage of the active agent or salt thereof.

8. The method according to any of claims 1-7, characterized in that it is a method for treating a disease or condition.

9. The method according to claim 8, characterized in that the disease or condition is selected from the group consisting of an endometrial disorder, a cancer, an inflammatory disorder, an infection, and any combination thereof.

10. The method according to claim 9, characterized in that the disease or condition is an endometrial disorder.

11. The method according to claim 10, characterized in that the endometrial disorder is endometriosis, adenomyosis, or a combination thereof.

12. The method according to claim 10 or 11, characterized in that the amount of an endometrial deposit is lower after vaginal administration of the pharmaceutical composition than the amount prior to vaginal administration of the pharmaceutical composition.

13. The method according to claim 9, characterized in that the disease or condition is a cancer.

14. The method according to claim 13, characterized in that the cancer is selected from the group consisting of cervical cancer; ovarian cancer; mesothelial cancer; peritoneal cancer; and any combination thereof.

15. The method according to claim 13 or 14, characterized in that the treatment comprises a reduction of a tumor size or a reduction of tumor growth.

16. The method according to claim 15, characterized in that the reduction of tumor size or reduction of tumor growth is determined by a reduction in a tumor volume as measured by ultrasound.

17. The method according to claim 9, characterized in that the disease or condition is an inflammatory disorder.

18. The method according to claim 17, characterized in that the inflammatory disorder is selected from the group consisting of: pelvic inflammatory disease; chronic pelvic pain; and any combination thereof.

19. The method according to claim 17 or 18, characterized in that the treatment comprises reducing an amount of at least one pro-inflammatory cytokine to an amount that is lower than prior to vaginal administration of the pharmaceutical composition.

20. The method according to claim 9, characterized in that the disease or condition is an infection.

21. The method according to claim 20, characterized in that the infection is a bacterial infection.

22. The method according to claim 20, characterized in that the infection is a viral infection.

23. The method according to claim 20, characterized in that the infection is a fungal infection.

24. The method according to any of claims 1-23, characterized in that the active agent or salt thereof is selected from the group consisting of a hormone; an antineoplastic agent; a GnRH agonist; a GnRH antagonist; a steroid; an antibiotic; an antiviral compound; an antifungal compound; an anti-inflammatory agent; a salt of any of these; and any combination thereof.

25. The method according to claim 24, characterized in that the active agent is the hormone or a salt thereof, and wherein the hormone or salt thereof is selected from the group consisting of: testosterone; estradiol; ethinylestradiol; progesterone; levonorgestrel; oxytocin; desogestrel; a synthetic progesterone; a salt of any of these; and any combination thereof.

26. The method according to claim 24, characterized in that the active agent is the antineoplastic agent or a salt thereof, and wherein the antineoplastic agent or salt thereof is selected from the group consisting of cyclophosphamide; methotrexate; 5-fluorouracil; doxorubicin; procarbazine; prednisolone; bleomycin; vinblastine; dacarbazine; cisplatin; epirubicin; dichloroacetate, a salt of any of these; and any combination thereof.

27. The method according to claim 24, characterized in that the active agent is a GnRH agonist, a GnRH antagonist, or a salt thereof, and wherein the GnRH agonist, GnRH antagonist, or salt thereof is selected from the group consisting of leuprolide; buserelin; histrelin; goserelin; deslorelin; nafarelin; triptorelin; cetrorelix; abarelix; ganirelix; ozarelix; degarelix; teverelix; a salt of any of these; and any combination thereof.

28. The method according to claim 24, characterized in that the active agent is the steroid or a salt thereof, and wherein the steroid or salt thereof is danazol or a salt thereof.

29. The method according to claim 24, characterized in that the active agent is the antibiotic or a salt thereof, and wherein the antibiotic or salt thereof is selected from the group consisting of Ceftobiprole; Ceftaroline; Clindamycin; Dalbavancin; Daptomycin; Linezolid; Mupirocin; Oritavancin; Tedizolide; Telavancin; Tigecycline; Vancomycin; an Aminoglycoside; a Carbapenem; Ceftazidime; Cefepime; Ceftobiprole; a Fluoroquinolone; Piperacillin; Ticarcillin; Linezolid; Streptogramin; Tigecycline; Daptomycin; a salt of any of these; and any combination thereof.

30. The method according to claim 24, characterized in that the active agent is the antiviral compound or a salt thereof, and wherein the antiviral compound or salt thereof is selected from the group consisting of Ceftobiprole; Ceftaroline; Clindamycin; Dalbavancin; Daptomycin; Linezolid; Mupirocin; Oritavancin; Tedizolid; Telavancin; Tigecycline; Vancomycin; an Aminoglycoside; a Carbapenem; Ceftazidime; Cefepime; Ceftobiprole; Fluoroquinolone; Piperacillin; Ticarcillin; Linezolid; Streptogramin; Tigecycline; Daptomycin; a salt of any of these; and any combination thereof.

31. The method according to claim 24, characterized in that the active agent is the antifungal compound or a salt thereof, and wherein the antifungal compound or salt thereof is selected from the group consisting of ciclopirox olamine; haloprogine; tolnaftate; undecylenate; topical nystatin; amorolfine; butenafine; naftifine; terbinafine; a salt of any of these; and any combination thereof.

32. The method according to claim 24, characterized in that the active agent is the anti-inflammatory agent or a salt thereof, and wherein the anti-inflammatory agent or salt thereof is selected from the group consisting of diclofenac; ketoprofen; ibuprofen; aspirin; a salt of any of these; and any combination thereof.

33. The method according to any of claims 1-32, characterized in that the pharmaceutical composition is administered in a dose of the active agent or salt thereof of at least approximately 50 mg, at least approximately 100 mg, at least approximately 150 mg, at least approximately 200 mg, at least approximately 250 mg, at least approximately 300 mg, at least approximately 350 mg, or at least approximately 400 mg.

34. The method according to any of claims 1-32, characterized in that the pharmaceutical composition is administered in a dose of the active agent or salt thereof per body weight of the subject of at least approximately 0.1 mg / kg, at least approximately 0.5 mg / kg, at least approximately 1 mg / kg, at least approximately 1.5 mg / kg, at least approximately 2 mg / kg, at least approximately 2.5 mg / kg, at least approximately 3 mg / kg, at least approximately 3.5 mg / kg, at least approximately 4 mg / kg, at least approximately 4.5 mg / kg, at least approximately 5 mg / kg, at least approximately 5.5 mg / kg, at least approximately 6 mg / kg, at least approximately 6.5 mg / kg, at least approximately 7 mg / kg, at least approximately 7.5 mg / kg, at least approximately 8 mg / kg, at least approximately 8.5 mg / kg, at least approximately 9 mg / kg, at least approximately 9.5 mg / kg, at least approximately 10 mg / kg, at least approximately 11 mg / kg, at least approximately 12 mg / kg, at least approximately 13 mg / kg, at least approximately 14 mg / kg, at least approximately 15 mg / kg, at least approximately 16 mg / kg, at least approximately 17 mg / kg, at least approximately 18 mg / kg, at least approximately 19 mg / kg, or at least approximately 20 mg / kg.

35. The method according to any of claims 1-32, characterized in that the pharmaceutical composition comprises a substantially uniform mixture of an organic phase and an aqueous phase.

36. The method according to claim 35, characterized in that the organic phase comprises at least one oleogel comprising at least one oily agent and at least one water-insoluble cellulose polymer.

37. The method according to claim 36, characterized in that the water-insoluble cellulose polymer is an alkyl cellulose.

38. The method according to claim 37, characterized in that the alkyl cellulose is selected from the group consisting of methylcellulose; ethylcellulose; hydroxypropylcellulose; and any combination thereof.

39. The method according to claim 36, characterized in that the water-insoluble cellulose polymer is a cellulose containing carboxylic alkyl or a salt thereof.

40. The method according to claim 39, characterized in that the cellulose containing alkylcarboxylic acid is a carboxymethylcellulose that does not substantially contain sodium.

41. The method according to claim 40, characterized in that the substantially sodium-free carboxymethylcellulose comprises from approximately 1% to approximately 10% by weight of the total weight of the pharmaceutical composition.

42. The method according to claim 37, characterized in that the alkyl cellulose comprises from approximately 1% to approximately 10% by weight of the total weight of the pharmaceutical composition.

43. The method according to claim 38, characterized in that it comprises ethylcellulose, wherein the ethylcellulose comprises from approximately 1% to approximately 10% by weight of the total weight of the pharmaceutical composition.

44. The method according to claim 39 characterized in that it comprises cellulose containing carboxylic cellulose or a salt thereof, wherein the carboxylic cellulose containing cellulose or a salt thereof comprises from approximately 1% to approximately 10% by weight of the total weight of the pharmaceutical composition.

45. The method according to claim 35, characterized in that the aqueous phase comprises at least one aqueous gel.

46. ​​The method according to claim 45, characterized in that the aqueous gel comprises at least one gelling agent.

47. The method according to claim 46, characterized in that at least one gelling agent is selected from the group consisting of a carbomer; a poloxamer; sodium carboxymethylcellulose; and a combination thereof.

48. The method according to claim 46 or 47, characterized in that at least one gelling agent comprises from approximately 0.1% to approximately 10% by weight of the total weight of the aqueous gel.

49. The method according to any of claims 46-48, characterized in that the at least one gelling agent comprises from approximately 0.01% to approximately 10% by weight of the total weight of the pharmaceutical composition.

50. The method according to claim 36, characterized in that the oily agent is selected from the group consisting of: a monoglyceride; a diglyceride; a triglyceride; and any combination thereof.

51. The method according to claim 36, characterized in that the oily agent is isolated and purified.

52. The method according to claim 36, characterized in that the oily agent is selected from the group consisting of: a synthetic diglyceride; a synthetic triglyceride; a propylene glycol isostearate; a mixture of polyoxyethinelated oleic glycerides; an oil of plant origin; and any combination thereof.

53. The method according to claim 52, characterized in that it comprises propylene glycol isostearate, wherein the propylene glycol isostearate comprises from approximately 0.2% to approximately 2% by weight of the total weight of the pharmaceutical composition.

54. The method according to claim 52, characterized in that it comprises the polyoxyethylenated oleic glyceride mixture, wherein the polyoxyethylenated oleic glyceride mixture comprises from approximately 0.2% to approximately 2% by weight of the total weight of the pharmaceutical composition.

55. The method according to any of claims 35-54, characterized in that the organic phase is in a ratio of approximately 10:90 to approximately 90:10 by weight with respect to the aqueous phase.

56. The method according to any of claims 1-55, characterized in that the bioadhesive is selected from the group consisting of: a carbomer; glyceryl monooleate; hypromellose; polycarbophil; poly(methyl vinyl ether co-maleic anhydride); a salt thereof; and a combination thereof.

57. The method according to claim 56, characterized in that the bioadhesive is polycarbophil, a salt thereof, or a combination thereof. cezQnn / eznz / e / Yi 58. The method according to any of claims 1-57, characterized in that the pharmaceutical composition comprises an alcohol concentration of approximately 0% to approximately 4% by weight based on the total weight of the pharmaceutical composition, and wherein the alcohol is either ethanol or isopropanol.

59. The method according to claim 58, characterized in that the alcohol concentration is approximately 3.5% by weight based on the total weight of the pharmaceutical composition.

60. The method according to any of claims 1-57, characterized in that the active agent comprises from approximately 0.00001% to approximately 10% by weight of the total weight of the pharmaceutical composition.

61. The method according to any of claims 1-57, characterized in that the pharmaceutical composition comprises from approximately 0% to approximately 4% of a penetration enhancer by weight of the total weight of the pharmaceutical composition.

62. The method according to any of claims 1-57, characterized in that the pharmaceutical composition comprises from approximately 0% to approximately 2% of a surfactant by weight of the total weight of the pharmaceutical composition, wherein the surfactant is selected from the group consisting of non-ionic; cationic; amphoteric; zwitterionic; and any combination thereof.

63. The method according to any of claims 1-62, characterized in that the pharmaceutical composition is administered to the subject in the form of a unit dose.

64. The method according to any of claims 1-62, characterized in that the vaginal administration of the pharmaceutical composition is carried out approximately every hour, approximately every 4 hours, approximately every 8 hours, approximately every 12 hours, or approximately every 24 hours.

65. The method according to any of claims 1-62, characterized in that the vaginal administration of the pharmaceutical composition is carried out approximately once, approximately twice, approximately 3 times, approximately 4 times, approximately 5 times, approximately 6 times, approximately 7 times, or approximately 8 times within 24 hours.

66. The method according to any of claims 1-62, characterized in that the vaginal administration of the pharmaceutical composition is carried out approximately once, approximately twice, approximately 3 times, approximately 4 times, approximately 5 times, approximately 6 times, approximately 7 times, approximately 8 times, approximately 9 times, approximately 10 times, approximately 11 times, approximately 12 times, approximately 13 times, approximately 14 times, approximately 15 times, approximately 16 times, approximately 17 times, approximately 18 times, approximately 19 times, or approximately 20 times a week.

67. The method according to any of claims 1-62, characterized in that the vaginal administration of the pharmaceutical composition is carried out approximately once, approximately twice, approximately 3 times, approximately 4 times, approximately 5 times, approximately 6 times, approximately 7 times, approximately 8 times, approximately 9 times, approximately 10 times, approximately 11 times, approximately 12 times, approximately 13 times, approximately 14 times, approximately 15 times, approximately 16 times, approximately 17 times, approximately 18 times, approximately 19 times, approximately 20 times, approximately 21 times, approximately 22 times, approximately 23 times, approximately 24 times, approximately 25 times, approximately 26 times, approximately 27 times, approximately 28 times, approximately 29 times, approximately 30 times, or approximately 31 times a month.

68. The method according to any of claims 1-67, characterized in that the pharmaceutical composition is applied with a finger.

69. The method according to any of claims 1-67, characterized in that the pharmaceutical composition is applied with a glove.

70. The method according to any of claims 1-67, characterized in that the pharmaceutical composition is applied with an applicator.

71. The method according to any of claims 1-67, characterized in that the vaginal administration comprises intravaginal administration, topical administration, suppository administration, or any combination thereof.

72. The method according to any of claims 1-71, characterized in that the pharmaceutical composition maintains a substantially stable, uniform appearance for a period of approximately 1 year when stored in a sealed container, at approximately 25°C, at approximately 1 atm of pressure, and approximately 50% relative humidity.

73. A pharmaceutical composition, characterized in that it comprises: (a) at least one oleogel comprising at least one oily agent and at least one water-insoluble cellulose polymer; (b) at least one aqueous gel; (c) an active agent or salt thereof; and (d) a bioadhesive; wherein the active agent or salt thereof is present in the pharmaceutical composition in an amount of approximately 50 mg to approximately 400 mg.

74. The pharmaceutical composition according to claim 73, characterized in that the at least one oleogel and the at least one aqueous gel are in the form of an emulsion.

75. The pharmaceutical composition according to claim 73 or 74, characterized in that the active agent or salt thereof is selected from the group consisting of a hormone; an antineoplastic agent; a GnRH agonist; a steroid; an antibiotic; an antiviral compound; an antifungal compound; an anti-inflammatory agent; a salt of any of these; and any combination thereof.

76. The pharmaceutical composition according to claim 75, characterized in that the active agent is the hormone or a salt thereof, and wherein the hormone or salt thereof is selected from the group consisting of: estradiol; ethinylestradiol; progesterone; levonorgestrel; desogestrel; a synthetic progesterone; a salt of any of these; and any combination thereof.

77. The pharmaceutical composition according to claim 75, characterized in that the active agent is the antineoplastic agent or a salt thereof, and wherein the antineoplastic agent or salt thereof is selected from the group consisting of cyclophosphamide; methotrexate; 5-fluorouracil; doxorubicin; procarbazine; prednisolone; bleomycin; vinblastine; dacarbazine; cisplatin; epirubicin; dichloroacetate, a salt of any of these; and any combination thereof.

78. The pharmaceutical composition according to claim 75, characterized in that the active agent is the GnRH agonist, the GnRH antagonist, or a salt thereof, and wherein the GnRH agonist, the GnRH antagonist, or a salt thereof is selected from the group consisting of leuprolide; buserelin; histrelin; goserelin; deslorelin; nafarelin; triptorelix; cetrorelix; abarelix; ganirelix; ozarelix; degarelix; teverelix; a salt of any of these; and any combination thereof.

79. The pharmaceutical composition according to claim 75, characterized in that the active agent is the steroid or a salt thereof, and wherein the steroid or salt thereof is danazol or a salt thereof.

80. The pharmaceutical composition according to claim 75, characterized in that the active agent is the antibiotic or a salt thereof, and wherein the antibiotic or salt thereof is selected from the group consisting of ceftoliprole; ceftaroline; clindamycin; dalbavancin; daptomycin; linezolid; mupirocin; oritavancin; tedizolid; telavancin; tigecycline; vancomycin; an aminoglycoside; a carbapenem; ceftazidime; cefepime; ceftoliprole; a fluoroquinolone; piperacillin; ticarcillin; linezolid; streptogramin; tigecycline; daptomycin; a salt of any of these; and any combination thereof.

81. The pharmaceutical composition according to claim 75, characterized in that the active agent is the antiviral compound or a salt thereof, and wherein the antiviral compound or salt thereof is selected from the group consisting of Ceftobiprole; Ceftaroline; Clindamycin; Dalbavancin; Daptomycin; Linezolid; Mupirocin; Oritavancin; Tedizolide; Telavancin; Tigecycline; Vancomycin; an Aminoglycoside; a Carbapenem; Ceftazidime; Cefepime; Ceftobiprole; Fluoroquinolone; Piperacillin; Ticarcillin; Linezolid; Streptogramin; Tigecycline; Daptomycin; a salt of any of these; and any combination thereof.

82. The pharmaceutical composition according to claim 75, characterized in that the active agent is the antifungal compound or a salt thereof, and wherein the antifungal compound or salt thereof is selected from the group consisting of ciclopirox olamine; haloprogine; tolnaftate; undecylenate; topical nysatin; amorolfine; butenafine; naftifine; terbinafine; a salt of any of these; and any combination thereof.

83. The pharmaceutical composition according to claim 75, characterized in that the active agent is the anti-inflammatory or a salt thereof, and wherein the anti-inflammatory or salt thereof is selected from the group consisting of diclofenac; ketoprofen; ibuprofen; aspirin; a salt of any of these; and any combination thereof.

84. A kit, characterized in that it comprises a container comprising the pharmaceutical composition in accordance with any of claims 73-83 and instructions for use.

85. A method for manufacturing a kit, characterized in that it comprises placing the pharmaceutical composition in accordance with any of claims 73-83 in a container.

86. A method for detecting danazol or a salt thereof in a sample, characterized in that it comprises: (a) contacting a portion of the sample from a subject with an albumin; and (b) detecting danazol or a salt thereof by mass spectrometry.

87. The method according to claim 86, characterized in that the detection comprises a determination of a quantity of an ion [M+H]+ comprising an m / z of 338.

88. The method according to claim 87, characterized in that the detection comprises a comparison of the amount of the [M+H]+ ion comprising the m / z of 338 to an amount of an [M+H]+ ion from an internal standard; wherein the internal standard is 19Norethindrone or a salt thereof.

89. The method according to claim 86, characterized in that the albumin is human serum albumin. cezQnn / eznz / e / Yi 90. The method according to claim 86, characterized in that the sample is dried and reconstituted in a buffer solution between (a) and (b).

91. A kit for determining the amount of danazol in a sample, characterized in that it comprises: (a) a sample collection container; (b) an albumin; and (c) instructions for use.

92. The kit according to claim 91, further characterized in that it comprises an internal standard; wherein the internal standard is 19-Norethindrone or a salt thereof.

93. The kit according to claim 91, further characterized in that it comprises a damping solution.

94. The kit according to claim 91, characterized in that the instructions for use instruct a user to: (a) collect a sample in the sample collection container; (b) contact a portion of the sample with a quantity of the albumin; and (c) detect danazol or a salt thereof by mass spectrometry.